To see the other types of publications on this topic, follow the link: Ju zhu jian zhu.
Journal articles on the topic 'Ju zhu jian zhu'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Ju zhu jian zhu.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Ma, Xiaowei, Bryan D. Wood, and Brian Way. "Application of Tetraethylsulfamide (TES) As a Cathode Additive in Cylindrical Cells." ECS Meeting Abstracts MA2022-01, no. 2 (2022): 357. http://dx.doi.org/10.1149/ma2022-012357mtgabs.
Full textAbstract:
Recently, sulfonamides have been shown to be promising electrolyte components due to their high chemical and electrochemical stability in lithium batteries [1, 2]. The electrolyte stability becomes critical when applying high voltage and/or utilizing Ni-rich layered oxides in high energy density lithium-ion batteries. Another approach to successful Ni-rich cathode performance is to develop a stable and effective cathode electrolyte interphase (CEI). Given the success of sultones and sulfates in this regard [3, 4], it is hypothesized that nitrogen analogs, like sulfonamides, could be tailored to provide a similar benefit. Indeed, Yim et al. [5, 6] have shown that N,N,N’,N’-tetraethylsulfamide (TES) forms a CEI on NMC811 that imparts high voltage cycling stability and less cathode corrosion. Our earlier studies of TES with Ni-rich NCA also formed a favorable CEI and these results are the topic of this presentation. Herein, we examine the performance of 0 - 4 wt.% TES in our commercially available, high power INR18650-P28A. These cells contain a composite SiO/graphite anode in addition to a Ni-rich cathode. As shown in Fig 1, TES significantly decreased the impedance of the cathode interface after conditioning compared to the control electrolyte. Thereafter, cells containing up to 2%TES show improved capacity retention during long-term high-rate cycling (+1C/-80W). Part of this success was due to a suppression of resistance growth during cycling by TES. Fast charge cycling (+3C/-2C), however, was moderately impaired with increased TES. Considering the largely reduced impedance of the cathode, fast-charge performance may have suffered due to anode rate limitations. These results will be discussed as well as gas generation, storage performance, and additional rate and cycling tests. [1] Shuting Feng, Mingjun Huang, Jessica R. Lamb, Wenxu Zhang, Ryoichi Tatara, Yirui Zhang, Yun Guang Zhu, Collin F. Perkinson, Jeremiah A. Johnson, Yang Shao-Horn. Chem, 5, 2630-2641 (2019) [2] Weijiang Xue, Mingjun Huang, Yutao Li, Yun Guang Zhu, Rui Gao, Xianghui Xiao, Wenxu Zhang, Sipei Li, Guiyin Xu, Yang Yu, Peng Li, Jeffrey Lopez, Daiwei Yu, Yanhao Dong, Weiwei Fan, Zhe Shi, Rui Xiong, Cheng-Jun Sun, Inhui Hwang, Wah-Keat Lee, Yang Shao-Horn, Jeremiah A. Johnson, Ju Li. Nature Energy, 6, 495-505 (2021) [3] Koji Abe, Manuel Colera, Kei Shimamoto, Masahide Kondo, Kazuhiro Miyoshi. Journal of Electrochemical Society, 161 (6) A863-A870 (2014) [4] Jian Xia, N. N. Sinha, L. P. Chen, J. R. Dahn. Journal of Electrochemical Society, 161 (3) A264-A274 (2014) [5] Kwangeun Jung, Taeeun Yim. Journal of Alloys and Compounds, 834,155155 (2020) [6] Ji Won Kim, Kwangeun Jung, Taeeun Yim. Journal of Mater. Sci & Tech. 86, 70-76 (2021) Figure 1
2
Zhu, Fang, Cunxiang Ju, Hongyan Sun, et al. "Abstract 930: Novel orthotopic pancreatic cancer cell lines derived from B6-KPC mice." Cancer Research 82, no. 12_Supplement (2022): 930. http://dx.doi.org/10.1158/1538-7445.am2022-930.
Full textAbstract:
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies due to its late diagnosis and limited response to treatment. B6-KPC mice ( LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre) generate spontaneous PDAC which could recapitulate the pathogenesis and genomic features of human PDAC. Although B6-KPC model is a wildly used for the exploration of the mechanisms of PDAC, some drawbacks of the model, such as long time for tumorigenesis, individual variation and difficulties in tumor observation, limit its application in cancer therapy. It is necessary to develop the pancreatic tumor cell lines from these models. In this study, we successfully established and well-characterized the luciferase-labled cell line mPAKPC-Luciferase. This cells carried the KrasG12D and Trp53R172H mutation. The orthotopic mPAKPC-Luciferase tumor model was well established by implanting tumor cell line into pancreas of B6 wild type mice and the tumor growth was traced by in vivo imaging. Moreover, Gemcitabine or combined with CD40 agonist presented significant tumor growth inhibition in B6 bearing mPAKPC-Luciferase orthotopic mouse models. While anti-PD1 or anti-OX40 had no anti-tumor effects in this model accordance with the low T cell infiltration of mPAKPC modle as a “cold” tumor. In addition, the immune profiling of this cell line showed highly expressed of potential therapeutic targets, including Claudin 18.2, CD47, CD73. Thus, mPAKPC-Luciferase cell lines are valuable models for the PDAC preclinical therapies. Citation Format: Fang Zhu, Cunxiang Ju, Hongyan Sun, Weiwei Yu, Chao Ju, Shuai Li, Yunlong Jiang, Dongjing Jia, Steve Smith, Zhiying Li, Jing Zhao, Xiang Gao. Novel orthotopic pancreatic cancer cell lines derived from B6-KPC mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 930.
3
de Goldfiem, Jacques. "Remaniement au sommet du Parti et de l'Etat [Wu Bangguo, Huang Ju, Jiang Chunyun, Song Ruixiang, Sun Jiazheng, Guo Zhenqian, Zhu Xun, Ai Zhisheng et Lu Peijian]." Perspectives chinoises 25, no. 1 (1994): 21–27. http://dx.doi.org/10.3406/perch.1994.1776.
Full text
4
Aditya Nugroho, Wiwid. "Perilaku Bisnis Islami Tao Zhu Gong : Sebuah Pembelajaran (‘Ibrah)." FALAH: Jurnal Ekonomi Syariah 1, no. 1 (2016): 64. http://dx.doi.org/10.22219/jes.v1i1.2697.
Full textAbstract:
Perilaku Bisnis Islami Tao Zhu Gong :Sebuah Pembelajaran (‘Ibrah)Wiwid Aditya NugrohoMagister Manajemen,Sekolah Pascasarjana Universitas HAMKA, JakartaE-mail: wiwidnugroho@yahoo.comABSTRAKBisnis sudah menjadi bagian kehidupan orang Cina yang tidak dapat terpisahkan. Hal ini pula yang menjadikan mereka sebagai salah satu sumber ilmu bisnis terpercaya karena kesuksesannya telah terbukti diseluruh dunia. Salah satunya adalah Tao Zhu gong yang mempunyai nama asli Fan li merupakan orang kepercayaan kaisar yue, yaitu Gou jian sekitar abad 500 SM. Tao Zhu-gong seorang ahli strategi militer yang mengundurkan diri dari kedudukan tinggi seorang perdana mentri untuk menjadi seorang pebisnis dan milyuner pertama di China. Karyanya yang terkenal adalah Kaidah emas keberhasilan Bisnis. Penelitian ini mencoba untuk membahas tentang 12 prinsip bisnis menurut Tao Zhu-gong. serta bagaimana 12 prinsip bisnis Tao Zhu-gong dalam perspektif Islam. Dengan menggunakan metode dokumentasi dan metode pendekatan historis (historical approach) penulis berkesimpulan bahwa sebagian dari 12 prinsip bisnis menurut Tao Zhu-gong mengandung nilai-nilai Islam, dan sebagian lainnya tidak sesuai dengan nilai Islam, disebabkan ketiadaan nilai spiritual didalamnya.Kata Kunci: Prinsip, Bisnis Islam, Pembelajaran (‘Ibrah)
5
유정은. "A Study on the Major Works of Zhu Jian Er." Music and Culture ll, no. 19 (2008): 53–82. http://dx.doi.org/10.17091/kswm.2008..19.53.
Full text
6
JIANG, Wen-Yue. "A neglected master on integrative medicine: Wei-Ju ZHU." Journal of Chinese Integrative Medicine 4, no. 3 (2006): 243–46. http://dx.doi.org/10.3736/jcim20060304.
Full text
7
Wei, Heyi, and Wenhua Jiang. "Translation of the ‘Landscape Architecture’ Into Chinese and How to Build the Discipline of Landscape Architecture in China?" International Research in Education 8, no. 1 (2020): 104. http://dx.doi.org/10.5296/ire.v8i1.16381.
Full textAbstract:
The translation and connotation of landscape architecture (LA) caused a lot of controversy in academia when the term ‘LA’ was introduced to China. In this study, we summarized the different opinions of Chinese scholars based on the origin, evolution, and professional contents of LA, which can be divided into ‘Jing Guan Jian Zhu’ (Chinese Pinyin), ‘Jing Guan She Ji’, and ‘Feng Jing Yuan Lin’. Finally, this article provides strategies and suggestions for enhancing the development of LA when the first-level discipline is established in China, and the aim is to narrow the gap with the international community.
8
Pan, Xing Yu, and Hong Yuan Fu. "Numerical Prediction of Settlement Adjacent to Deep Excavation of Metro Station in Ju-Zi-Zhou Island, Changsha." Applied Mechanics and Materials 204-208 (October 2012): 1484–87. http://dx.doi.org/10.4028/www.scientific.net/amm.204-208.1484.
Full textAbstract:
It is of great significant to predict the influence of deep excavation in Ju-Zi-Zhou island, so that damage to adjacent ancient tree, and Xiang-jiang Bridge could be prevented. Based on analysis of site condition, geological profile, and strut design, the numerical model was generated in commercial available software package Flac3D, in which Mohr-Coulomb model was introduced. Then, the settlements at several key points on the ground were evaluated in each step of excavation. The calibrated results shows that, the calculated settlement agrees well with the measured. So it can be applied to predict completed state and provide a guidance for next construction.
9
이병주. "A Book ReviewMao Zedong’s Korean War-ina crosses the Yalu River, written by Zhu Jian-rong." military history ll, no. 63 (2007): 113–46. http://dx.doi.org/10.29212/mh.2007..63.113.
Full text
10
Liu, Xiaoyu, Jing Lin, Qing Wang, Siyao Xiao, and Ling Wang. "Prescription rules of Qingzhu Fu, Ziming Chen, and Qian Wu for threatened miscarriage based on traditional Chinese medicine inheritance auxiliary platform." Traditional Medicine and Modern Medicine 03, no. 03 (2020): 185–90. http://dx.doi.org/10.1142/s257590002050010x.
Full textAbstract:
Background: To explore the prescription rules of famous ancient physicians in the treatment of threatened miscarriage. Methods: Traditional Chinese Medicine (TCM) prescriptions for threatened miscarriage were screened out of Fu Ren Da Quan Liang Fang by Ziming Chen, Yi Zong Jin Jian by Qian Wu, and Fu Qing Zhu Nv Ke by Qingzhu Fu. Data were standardized and analyzed through the TCM inheritance auxiliary platform. Results: A total of 29 prescriptions for threatened miscarriage were screened. Dang Gui, E Jiao, Gan Cao, Chuan Xiong, Bai Shao were the top five frequently prescribed Chinese herbs. The common herb–herb combinations used by Ziming Chen contained E Jiao, Dang Gui, Chuan Xiong, Ai Ye, Cong Bai, and Sang Ji Sheng. Ren Shen, Gan Cao, and Bai Zhu were the common herbal groups used by Qingzhu Fu. Huang Qi, Shu Di Huang, Bai Shao, Dang Gui, and Gan Cao were one of Qian Wu’s core prescriptions, with Dang Gui and Chuan Xiong being the others. According to the analysis of four Qi, five flavors, and meridian tropism of the prescriptions, herbs with the warm nature, or with the sweet, pungent, bitter flavors topped the list of application. The top six meridian tropisms of high-frequency herbs were: liver, spleen, lung, kidney, heart, and stomach meridian. Conclusion: Based on the principle of restoring the balance within the organs and enriching Qi and blood, clinical treatment of threatened miscarriage involves invigorating the Chong and Ren channels, nourishing Yin, dispelling cold and wind, generating and activating blood, regulating and harmonizing Qi.
11
Wang, Shufang, Pinghong Chen, Wei Jiang, et al. "Identification of the effective constituents for anti-inflammatory activity of Ju-Zhi-Jiang-Tang, an ancient traditional Chinese medicine formula." Journal of Chromatography A 1348 (June 2014): 105–24. http://dx.doi.org/10.1016/j.chroma.2014.04.084.
Full text
12
Yi, Guo, and Martin Lu. "Guodian Bamboo Texts and Pre-Qin Intellectual Thoughts (Guo Dian Zhu Jian Yu Xian Qin Xue Shu Si Xiang)a." Journal of Chinese Philosophy 31, no. 2 (2004): 297–301. http://dx.doi.org/10.1111/j.0301-8121.2004.155_1.x.
Full text
13
Sui, Minghong, Naifu Jiang, Luhui Yan, et al. "Effect of Electroacupuncture on Shoulder Subluxation in Poststroke Patients with Hemiplegic Shoulder Pain: A Sham-Controlled Study Using Multidimensional Musculoskeletal Ultrasound Assessment." Pain Research and Management 2021 (November 19, 2021): 1–9. http://dx.doi.org/10.1155/2021/5329881.
Full textAbstract:
Objective. This study aimed to use multidimensional musculoskeletal ultrasound imaging technique to investigate the effect of electroacupuncture (EA) on shoulder subluxation in poststroke patients with hemiplegic shoulder pain. Methods. In this prospective single-blind, randomized, sham-controlled study, thirty-four patients with shoulder subluxation and hemiplegic shoulder pain were recruited and randomly assigned into the EA group or the sham EA (SEA) group. In the EA group, EA was applied to the Jian yu (LI15), Bi nao (LI14), Jian zhen (SI9), and Jian liao (TE14) acupoints. In the SEA group, the EA was applied 15 mm away from the Lou gu (SP7), Di ji (SP8), Jiao xin (KI8), and Zhu bin (KI9) acupoints. Both groups underwent treatment 30 minutes/day, five days a week, for two weeks using dense waves with a frequency of 2/100 Hz. A Visual Analogue Scale (VAS) was used to evaluate the effectiveness of treatment in reducing shoulder pain. Musculoskeletal ultrasound was used to evaluate the changes of measures of shoulder subluxation in multidimensions (i.e., the acromiohumeral distance, AHD; acromion-greater tuberosity, AGT; and acromion-lesser tuberosity, ALT). Both the within- and between-groups treatment effects were assessed. Results. The pain intensity measured by VAS and shoulder subluxation measured by musculoskeletal ultrasound (i.e., AHD, AGT, and ALT) showed significant ( p < 0.05 ) within-group difference in both groups. The between-group difference appeared in the pain intensity ( p < 0.05 ), while it disappeared in the three measures of shoulder subluxation ( p > 0.05 ). Conclusions. Using VAS for measuring pain intensity and multidimensional musculoskeletal ultrasound imaging technique for measuring shoulder subluxation, this study finds that the hemiplegic shoulder pain can be improved significantly by the EA while the shoulder subluxation cannot be. Our findings further reveal the analgesic mechanism of EA on hemiplegic shoulder pain following stroke.
14
Lin, Yuehe, and Dan (Annie) Du. "(Invited) New Bioinspired Nanomaterials for Biosensing and Cancer Theranostics." ECS Meeting Abstracts MA2022-01, no. 53 (2022): 2202. http://dx.doi.org/10.1149/ma2022-01532202mtgabs.
Full textAbstract:
Nature is an excellent source of inspiration for the widespread application of science and technology. Researchers learn from biological principles and gradually develop from the earliest direct use of biological materials to the design and development of new biomimetic materials inspired by nature. Therefore, the innovation of bioinspired nanomaterials will enable tremendous advances in biology and biochemistry with biomimetic capabilities, such as biosensing, cell imaging, and drug delivery. In this presentation, I will discuss my group’s recent work on two bioinspired nanomaterials: nano-peptoids and single-atom nanozymes. The first type of bioinspired materials is a sequence-defined peptide-like materials that can mimic the structure and function of peptides and proteins. Compared with peptides and proteins, peptoids have a high degree of thermal and chemical stability, and are resistant to proteolytic degradation. In addition, due to the lack of intramolecular and intermolecular backbone hydrogen bond donors, it is possible to precisely control the peptoid and peptoid-substrate interactions, leading to bio-inspired synthesis of nanomaterials with a layered structure. As a peptide mimic, the peptoids has biocompatibility, non-toxicity and sequence-specific heteropolymers. Nano-peptoids can be synthesized with polar and hydrophobic monomers and have the following advantages: They can be easily processed into desired shapes (e.g. dendritic, sheets, tubes and vesicles), and the size range is 2-100 nm to enhance cell targeting and uptake. The application of nano-peptoids in cell imaging and cancer theranostics will be discussed. Another type of bioinspired nanomaterials with enzyme-like properties is single-atom nanoenzymes. As a biocatalyst, natural enzymes have the ability to accelerate various reaction rates with extremely high activity and selectivity under mild conditions. However, due to the temperature and pH-related denaturation of proteins and the possibility of contamination by bacteria or other reagents, the shelf life of natural enzymes is limited or uncertain, and their purification and production costs are high. Therefore, natural enzymes must narrow the range of conditions under which they can be used, limiting their further applications in biosensing and biomedicine. R Recent research has focused on the rational design of nanomaterials with inherent enzyme-like catalytic properties (for example, oxidase, peroxidase, catalase, superoxide dismutase, and so on) and exploration of their applications in various fields. Although much progress has been made, the development of nanozymes is still hampered by several challenges. Catalytic activity and substrate selectivity are the two most important issues that need to be resolved to allow the technology to reach full maturity. Therefore, rational design and tuning of nanomaterials is highly desirable for the development of novel enzyme-mimic nanomaterials with precise catalytic sites. We have developed various Fe-N-C based single atomic site catalysts which have similar structure with active site of peroxidase. These atomically-dispersed Fe-N-C materials have enzyme-like properties, therefore they are classified as single-atom nanozymes. Together with their abundantly exposed active sites and specific structures, these single atomic nanozymes have great potential for the enhancement of biocatalytic activity and selectivity in biosensing. Jiao, H. Yan, Y. Wu, W. Gu, C. Zhu, D. Du, Y. Lin. When Nanozymes Meet Single-Atom Catalysis. Angew. Chem. Int. Ed. 2020,132, 2585-2596 Zhu, S. Fu, Q. Shi, D. Du, Y. Lin. Single-Atom Electrocatalysts. Angew. Chem. Int. Ed. 2017, 56, 13944-13960. Cheng, J. Li, D. Liu, Y. Lin, D. Du. Single-Atom Nanozyme Based on Nanoengineered Fe-N-C Catalyst with Superior Peroxidase-Like Activity for Ultrasensitive Bioassays. Small, 2019, 1901485. Niu, Q. Shi, W. Zhu, D. Liu, H. Tian, S. Fu, N. Cheng, S. Li, J. N Smith, D. Du, Y. Lin. Unprecedented Peroxidase-mimicking Activity of Single-atom Nanozyme with Atomically Dispersed Fe-Nx Moieties Hosted by MOF Derived Porous Carbon. Biosensors & Bioelectronics, 2019, 142, 111495. Jiao, W. Xu, Y. Wu, H. Yan, W. Gu, D. Du, Y Lin, C. Zhu, Single-atom Catalysts Boost Signal Amplification for Biosensing. Chemical Society Reviews 2021, 50, 750-765 Luo, Y. Song, M. Wang, T. Jian, S. Ding, P. Mu, Z. Liao, Q. Shi, X. Cai, H. Jin, D. Du, W. Dong, C. Chen, Y. Lin. Bioinspired Peptoid Nanotubes for Targeted Tumor Cell Imaging and Chemo-Photodynamic Therapy. Small 2019, 1902485. Song, M. Wang, S. Akkineni, W. Yang, J.J. Hettige, H. Jin, Z. Liao, P. Mu, F. Yan, M. Baer, J. De Yoreo, D. Du, Y. Lin, C. Chen. Highly Bright and Photostable Two-Dimensional Nanomaterials Assembled from Sequence-Defined Peptoids. ACS Materials Letters 2021, 3, 420-427. Cai, M. Wang, P. Mu, T. Jian, D. Liu, S. Ding, Y. Luo, D. Du, Y. Song, C. Chen, Y. Lin. Sequence-Defined Nanotubes Assembled from IR780-Conjugated Peptoids for Chemophototherapy of Malignant Glioma. Research 2021, Article ID 9861384.
15
Lu, Da-Yong, Peng-Peng Zhu, Hong-Ying Wu, Bin Xu, Jian Ding, and Ting-Ren Lu. "RETRACTED: Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery." Central Nervous System Agents in Medicinal Chemistry 19, no. 1 (2019): 15–23. http://dx.doi.org/10.2174/1871524919666190115130655.
Full textAbstract:
The article entitled “Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery”, by Da-Yong Lu, Peng-Peng Zhu, Hong-Ying Wu, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Ajit Varki and Ting-Ren Lu, has been retracted on the request of one co-authors, Dr. Ajit Varki and Dr. Nagendra Sastry Yarla available at: Cent Nerv Syst Agents Med Chem 2019; 19(1): 15-23. http://www.eurekaselect.com/169003/article. The Corresponding Author Dr. Da-Yong Lu has included the names of the co-authors, Dr. Ajit Varki and Dr. Nagendra Sastry Yarla without their consent and the manuscript has been published in the journal, Central Nervous System Agents in Medicinal Chemistry (CNSAMC). Kindly see Bentham Science Policy on Article retraction at the link given below: (https://benthamscience.com/journals/central-nervous-system-agents-in-medicinal-chemistry/author-guidelines/) Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such, this article represents a severe abuse of the scientific publishing sys-tem. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
16
Chi, ZENG, and ZHU Jian-Yu. "Microcalorimetric Study of the Influence of Extracellular NaCl Concentration on the Growth Metabolism of Halobacterium halobiumZENG Chi1,* ZHU Jian-Yu." Acta Physico-Chimica Sinica 27, no. 06 (2011): 1525–30. http://dx.doi.org/10.3866/pku.whxb20110618.
Full text
17
Vicini, Stefano, Jian Feng Wang, Jin Hong Li, et al. "Functional and Pharmacological Differences Between RecombinantN-Methyl-d-Aspartate Receptors." Journal of Neurophysiology 79, no. 2 (1998): 555–66. http://dx.doi.org/10.1152/jn.1998.79.2.555.
Full textAbstract:
Vicini, Stefano, Jian Feng Wang, Jin Hong Li, Wei Jian Zhu, Yue Hua Wang, Jian Hong Luo, Barry B. Wolfe, and Dennis R. Grayson. Functional and pharmacological differences between recombinant N-methyl-d-aspartate receptors. J. Neurophysiol. 79: 555–566, 1998. N-methyl-d-aspartic acid (NMDA) receptors transiently transfected into mammalian HEK-293 cells were characterized with subunit-specific antibodies and electrophysiological recordings. Deactivation time course recorded in response to fastl-glutamate pulses were studied in isolated and lifted cells, as well as in outside-out membrane patches excised from cells expressing recombinant NR1 subunits in combination with the NR2A, NR2B, NR2C, or NR2D NMDA receptor subunits. Transfected cells were preidentified by the fluorescence emitted from the coexpressed Aequorea victoria jellyfish Green Lantern protein. Currents generated by NR1/NR2A channels displayed double exponential deactivation time course being faster than that in NR1/NR2B or NR1/NR2C channels. However, a large decay variability was observed within each cotransfection, suggesting that mechanisms additional to subunit composition may also regulate deactivation time course. NR1/NR2D channels displayed slowly deactivating currents. Channel deactivation was fast and comparable among receptors obtained by cotransfecting five distinct spliced variants of the NR1 subunit, each with the NR2A subunit. Additionally, recovery from desensitization was slower for NR1/NR2B than for NR1/NR2A channels. The average deactivation time course of responses to brief l-glutamate applications in cells where NR1/NR2A/NR2B cDNAs were cotransfected at variable ratio was intermediate between those of the NR1/NR2A and NR1/NR2B channels. Although immunocytochemical evidence indicates that the majority of cells are cotransfected by all plasmids in triple transfection, our experimental condition did not allow for a tight control of the expression of NMDA receptor subunits. This produced the result that many cells were characterized by deactivation time course and haloperidol sensitivities of separate NR1/NR2A and NR1/NR2B subunit heteromers. We also speculate on the possible formation of channels resulting from the coassembly in the same receptor of NR1/NR2A/NR2B subunits from a minority of cells that gave responses to brief application of l-glutamate characterized by slow deactivation time course and decreased haloperidol sensitivity.
18
김명신 та kwandong MIN. "The Study on San-he-ming-zhu-bao-jian-quan-zhuan (三合明珠寶劍全傳)'s Xylographic Book and Narration". Cross-Cultural Studies 31, № ll (2013): 65–94. http://dx.doi.org/10.21049/ccs.2013.31..65.
Full text
19
Hong, Mi Hyeon, Jin Seok Hwang, Byung Hyuk Han, et al. "Samchulkunbi-Tang Alleviates Vascular Endothelial Disorder and Renal Dysfunction in Nitric Oxide-Deficient Hypertensive Rats." Evidence-Based Complementary and Alternative Medicine 2021 (December 17, 2021): 1–11. http://dx.doi.org/10.1155/2021/8443952.
Full textAbstract:
Samchulkunbi-tang (SCT, Shen Zhu Jian pi tang in Chinese) is said to have been first recorded by Zheng Zhi Zhun Sheng during the Ming Dynasty in China. Records of SCT in Korea are known to have been cited in Donguibogam (Dong Yi Bao Jian in Chinese), Uibang Hwaltu (Yi Fang Huo Tao in Chinese), and Bang Yak Hapyeon (Fang Yao He Bian in China). Although SCT is widely used in treating chronic gastritis and gastric ulcers, the beneficial effect on renal vascular function is unknown. Hypertension is a risk factor for cardiovascular disease and endothelial dysfunction in humans and experimental animal models of arterial hypertension. In addition, kidney dysfunction is characterized by hypertension diseases. This study was conducted to evaluate the effect of SCT on the vascular function in vitro (human umbilical cord endothelial cells, HUVECs) and in vivo (NG‐nitro‐L‐arginine methyl ester, L-NAME-induced hypertensive rats). The phosphorylation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) is closely related to nitric oxide (NO) production in HUVECs, and SCT in this study significantly increased these. For three weeks, hypertensive rat models were induced by L-NAME administration (40 mg/kg/day) with portable water. It was followed by oral administration with 100 and 200 mg/kg/day for two weeks to confirm the effectiveness of SCT. As a result, systolic blood pressure decreased in the SCT-treated groups, compared with that in the L-NAME-induced hypertensive group. SCT treatment restored vasorelaxation by stimulating acetylcholine and cGMP production in the thoracic aorta. In addition, SCT treatment decreased intima-media thickness, attenuated the reduction of eNOS expression, and increased endothelin-1 expression. It also increased p-Akt and p-eNOS expression in hypertensive rat aorta. Furthermore, regarding renal function parameters, SCT ameliorated urine osmolality, urine albumin level, serum creatinine, and blood urea nitrogen levels. These results demonstrate that the oriental medicine SCT exerts potent vascular and renal protective effects on nitric oxide-deficient hypertensive rats and HUVECs
20
CHEN, XIAO-LIN, XIN-JIAN WANG, and CHAO-DONG ZHU. "XIAO-LIN CHEN, XIN-JIAN WANG & CHAO-DONG ZHU (2013) New species and records of Trypetinae (Diptera: Tephritidae) from China. Zootaxa, 3710(4), 333–353." Zootaxa 3718, no. 5 (2013): 500. http://dx.doi.org/10.11646/zootaxa.3718.5.7.
Full text
21
Martí-Vargas, José R. "Discussion of “Experimental Investigation of Pullout Behavior of Fiber-Reinforced Polymer Reinforcements in Sand” by Cheng-Cheng Zhang, Hong-Hu Zhu, Bin Shi, Fang-Dong Wu, and Jian-Hua Yin." Journal of Composites for Construction 19, no. 5 (2015): 07015004. http://dx.doi.org/10.1061/(asce)cc.1943-5614.0000575.
Full text
22
Zhang, Cheng-Cheng, Hong-Hu Zhu, Bin Shi, Fang-Dong Wu, and Jian-Hua Yin. "Closure to “Experimental Investigation of Pullout Behavior of Fiber-Reinforced Polymer Reinforcements in Sand” by Cheng-Cheng Zhang, Hong-Hu Zhu, Bin Shi, Fang-Dong Wu, and Jian-Hua Yin." Journal of Composites for Construction 19, no. 5 (2015): 07015005. http://dx.doi.org/10.1061/(asce)cc.1943-5614.0000593.
Full text
23
Ukritchon, Boonchai, and Suraparb Keawsawasvong. "Discussion of “Using a Pressurized Shield to Increase Face Stability of Circular Tunnels in Purely Cohesive Soil” by Wantao Ding, Shucai Li, Keqi Liu, Jian Zhu, Mingjiang Li, and Peihe Shi." International Journal of Geomechanics 20, no. 3 (2020): 07019008. http://dx.doi.org/10.1061/(asce)gm.1943-5622.0001611.
Full text
24
Ding, Wantao, Shucai Li, Keqi Liu, Jian Zhu, Mingjiang Li, and Peihe Shi. "Closure to “Using a Pressurized Shield to Increase Face Stability of Circular Tunnels in Purely Cohesive Soil” by Wantao Ding, Shucai Li, Keqi Liu, Jian Zhu, Mingjiang Li, and Peihe Shi." International Journal of Geomechanics 20, no. 3 (2020): 07019009. http://dx.doi.org/10.1061/(asce)gm.1943-5622.0001612.
Full text
25
Lu, Martin. "Guodian Bamboo Texts and Pre-Qin Intellectual Thoughts (Guo Dian Zhu Jian Yu Xian Qin Xue Shu Si Xiang).a By Guo Yi. b (Shanghai: Shanghai Educational Publishing House, 2001. 859 pp.)." Journal of Chinese Philosophy 31, no. 2 (2004): 297–301. http://dx.doi.org/10.1163/15406253-03102008.
Full text
26
德, 王永. "中等水平外国学生理解汉语句子的速度变化——基于抑制加工的研究". Chinese as a Second Language Research 5, № 1 (2016): 87–105. http://dx.doi.org/10.1515/caslar-2016-0004.
Full textAbstract:
AbstractA key index to learners’ proficiency level of a second language, the comprehension speed of sentences, is a pivotal factor that determines the choice of teaching method which may suit the second language learners in their learning of specialty courses. From the representation of inner knowledge of a second language and the character of its process, some researchers describe a quickening tendency of second language process speed during the acquisition of the language. With respect to the reason why the change of process speed occurs, however, researchers have not explained the difference between a learner’s mother tongue and second language, which may be important in practice. This study explores increasing speed of foreign students’ comprehension of Chinese sentences from the perspective of inhibition of processing.In this experiment, there are four groups of subjects, twenty in each and all paid for their participation. Three groups are native English, Japanese and Korean speakers, and the other group is Mandarin Chinese speakers selected as comparison. Ten constructions of Chinese sentences are chosen as the test materials, including three subject-verb-object constructions (zhu dong bin ju), subject-verb-agent construction (shi bin ju), two topic-comment constructions, two ba constructions, bei construction, and bei-ba compound construction. The six native Mandarin Chinese speakers, who do not actually participate in the experiment, score all the sentences in the experiment in terms of grammaticality. All the sentences, which are programmed, are presented one by one at random on the screen of a Pentium IV laptop, each followed by three possible answers about the actor of the action described in the sentence. The subjects should choose one answer among the three as accurately and quickly as possible by pressing a certain key on the keyboard. There are some sentences for pretesting before the formal experiment. In the formal experiment, reaction time and subject’s answer of each sentence are self-recorded. Reaction time and percent correct for each construction of Chinese sentences is calculated after the experiment. The post hoc multiple comparison tests are performed for the reaction time of each construction of Chinese sentences separately.SPSS analysis shows that: (1) there is a highly significant difference (P≈0.000﹤0.001) between all the groups of foreign students and the native Chinese speakers in the comprehension of all ten constructions of Chinese sentences except one of the topic-comment constructions (zhu ling ju) (P=0.018). (2) there is a significant difference (P﹤0.05) between the native English speakers and the native Japanese or Korean speakers in comprehending seven of the ten constructions of Chinese sentences.Compared the comprehension speed of sentences of foreign students when their Chinese knowledge is at the intermediate level with the primary level, the conclusions of this research are as follows:Firstly, the foreign students require to inhibit less and less inapposite knowledge in comprehending Chinese sentences with their improvement in Chinese knowledge, but they are less skilled than the Chinese students even if their Chinese knowledge is at the intermediate level; there is significant difference between the foreign students and the Chinese students. These results suggest that, even if foreign students’ Chinese ability reaches the intermediate level, they also require a separate organization to study. The effect would not be good if they were put together with native Chinese students to study professional courses.Secondly, when the foreign students are at the intermediate level of Chinese knowledge, their inhibition of inapposite knowledge is also related to their native languages in different typologies; there is significant difference between the students whose native language is English and those whose native languages are Japanese and Korean. But the difference between the two different categories students are diminished when their Chinese knowledge is at the intermediate level. These results suggest that, when the foreign students have a high level of Chinese, they could be organized to teach according to their actual differences, teaching content should be targeted for specific learners. The teacher should strengthen the grammar rules which are difficult for specific learners, increase the frequency of language input and practice.
27
Xiuling, Cao, та Liu Liu. "现代汉语总结类话语标记浅析 = Discourse Markers of Summary in Modern Chinese". Sinología hispánica 1, № 1 (2015): 59. http://dx.doi.org/10.18002/sin.v1i1.5182.
Full textAbstract:
<p>总结类话语标记是人类语言共有的元话语<br />成分之一。现代汉语总结类话语标记包括“总<br />之”、“一句话”、“概括起来讲”、“总的<br />来看”等众多成员，根据构成成分及其结构关<br />系特点可以归纳为以“话/言”和“说/讲/<br />看”为核心成分的名词和动词两个系列。总结<br />类话语标记分布在前后语段之间，构建的语篇<br />模式为“a，X，b”，在“要点概括”的总体语<br />义功能之下表达概括、推论、补充、转折、让<br />步等多种下位语义关系。总结类话语标记的语<br />篇组织功能和人际互动功能是其概念表达功能<br />语法化的结果，在这一过程中从基本话语发展<br />为元话语。</p><p>A discourse marker of summary is a common<br />meta-discourse element in human languages.<br />Discourse markers of summary in modern Chinese<br />contains zong zhi, yi ju hua, gai kuo qi lai jiang,<br />zong de lai kan and others, which can be<br />summarized as nouns and pronouns centered by<br />hua/yan, shuo/jiang/kan in correspondence of<br />their construction elements and features of<br />construction relation. Discourse markers of<br />summary distribute near the front and back<br />syntagms, through which the discourse model is<br />constructed as “a, X, b”. This construction<br />implies summary, inference, complementarity,<br />transference, concession, and other semantic<br />relation of subcategorization. The discourse<br />organizing function and inter-personal interactive<br />function of discourse markers of summary is the grammaticalization of the function of these<br />concepts and in this process, the discourse<br />markers of summary develops from basic<br />discourse to meta-discourse.</p>
28
Li, Feng, Siqi Zhou, Sai Chen, et al. "Erratum for “Preparation of Low-Temperature Phase Change Materials Microcapsules and Its Application to Asphalt Pavement” by Feng Li, Siqi Zhou, Sai Chen, Zhenglong Yang, Jian Yang, Xingyi Zhu, Yuchuan Du, Peiting Zhou, and Zhihao Cheng." Journal of Materials in Civil Engineering 31, no. 5 (2019): 08219001. http://dx.doi.org/10.1061/(asce)mt.1943-5533.0002678.
Full text
29
Zhou, Jian, Jian Yang, Zixiang Zhang, et al. "Abstract 5917: Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of patients with stages I-III colorectal cancer (CRC)." Cancer Research 82, no. 12_Supplement (2022): 5917. http://dx.doi.org/10.1158/1538-7445.am2022-5917.
Full textAbstract:
Abstract Background: Identifying molecular residual disease (MRD) with tailored tumor-informed ctDNA based next-generation sequencing (NGS) assays after curative surgery could facilitate the individualized management of resected CRC patients. Here, we investigated the clinical utility of tumor-informed ctDNA mutation analysis using a novel Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (PROPHET) approach for accessing MRD in resected CRC patients. Using the same set of baseline and post-operative blood samples, we compared the performance of PROPHET assay with tumor-naïve fixed panel for detecting MRD and predicting recurrence in resected CRC patients. Methods: The prospective study recruited 42 patients diagnosed with stage I-III CRC from May 2019 to Jun 2020 at the First Affiliated Hospital of Soochow University. Tumor tissue samples were collected at surgery. Blood samples collected before surgery (baseline), 8-day post-operative time point before any adjuvant therapy were analyzed. The detection and quantification of ctDNA for MRD assessment was investigated using PROPHET, a personalized, tumor-informed ctDNA assay designed to track up to 50 top-ranked patient-specific somatic variants based on whole-exome sequencing (WES) of the tumor tissue and matched white blood cells (WBCs). Tumor- naïve fixed assay was performed using targeted NGS panel, containing 41 gastrointestinal cancer-related genes. Results: Baseline ctDNA status was detected in 95.23% (40/42) of the patients with PROPHET assay, and 69.05% (29/42) of the patients with fixed panel. Of 42 patients included in the analysis, 1, 25, and 16 patients had pathological stages I, II, and III CRC with baseline ctDNA detected in 100% (1/1), 92% (23/25), 100% (16/16) patients with PROPHET assay, and 100% (1/1), 64% (16/25), 75% (12/16) patients with fixed panel. Post-operative ctDNA-positive status with PROPHET assay was associated with 3-year DFS, compared with ctDNA-negative group (hazard ratio [HR], 16.57, 95% confidence interval [CI]:3.01-91.36, p=0.014). 15% (6/40) patients were identified to be MRD- positive and 83.33% (5/6) patients eventually relapsed at 3-years follow-up. Although fixed panel also showed high performance in predicting relapse HR, 4.48, 95% CI:1.9-10.9; p&lt; 0.001, 27.5% (11/40) patients were identified to be MRD-positive and only 45.45% (5/11) patients eventually relapsed. 3-year prognostication with PROPHET assay at 8-day post-operation yielded higher positive predictive value (83.33% vs 45.45%), negative predictive value (91.18% vs 89.66%), and specificity (96.88% vs 81.25%) as compared with tumor-naïve fixed panel. Conclusion: Patient-specific PROPHET assay based on unique somatic mutation profiles detects patients with high-risk of recurrence, which achieved higher specificity than tumor-naïve fixed panel. Citation Format: Jian Zhou, Jian Yang, Zixiang Zhang, Ye Li, Bin Yi, Yuchen Tang, Dechun Li, Xiaozhe Li, Di Peng, XI Li, Yang Wang, Haiyan Li, Bing Li, Chenyang Wang, Pengfei Zhu, Longfei Chen, Shuailai Wu, Shuai Fang, Chenxi Li, Fujun Qiu, Shannon Chuai, Zhihong Zhang. Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of patients with stages I-III colorectal cancer (CRC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5917.
30
Zhu, Dandan, Jian Tu, Zijun Huo, et al. "Abstract 1616: Dissecting the biology and therapeutic vulnerabilities of RB1-mutant osteosarcoma using hereditary retinoblastoma iPSCs." Cancer Research 82, no. 12_Supplement (2022): 1616. http://dx.doi.org/10.1158/1538-7445.am2022-1616.
Full textAbstract:
Abstract Patients with hereditary retinoblastoma (RB), an inherited autosomal dominant cancer disordercaused by germline mutations/deletions in the RB1 gene, have a &gt;400 fold increased incidenceof osteosarcoma (OS), suggesting a strong mechanistic link between RB1 loss andosteosarcomagenesis. Although mice offer many advantages when conducting cancer research,unlike humans, Rb1 knockout mice do not develop OS, suggesting the urgent requirement foralternative disease models to understand how RB1 mutation leads to osteosarcomagenesis.Here, we generated patient-derived induced pluripotent stem cells (iPSCs) by reprogramming RBand healthy control fibroblasts and then created isogenic controls by correcting RB1 mutationusing CRISPR/Cas9. Performing in vitro soft-agar assay and in vivo xenografts, we foundpotential tumorigenic ability in RB osteoblasts (OBs) but not control OBs. In order to gain insightsinto RB1 loss associated osteosarcomagenesis, we compared global transcripts among RB andcontrol OBs. GSEA analysis indicated that OS associated genes are specifically enriched in RBOBs in comparison with control OBs, demonstrating that RB OBs acquire OS characteristics inthe absence of additional gene alterations. GO analysis revealed that genes involved in the mitoticcell cycle are enriched in RB OBs. Although RB1 is known to controlling G1/S related geneexpression by inhibiting E2F transcription factors, it is still nebulous if RB1 plays a role inregulating mitotic genes.To comprehensively identify preferential binding of RB1 to specific promoters in OBs, weconducted RB1 ChIP-seq to map genome-wide RB1-binding sites in iPSC-derived OBs. SinceE2F3a, a RB1 repressed transcription factor, is enriched expressed in OBs, we also performedE2F3a ChIP-seq to define whether these RB1-repressed targets are E2F3a-activated targets.Using the nonbiased de novo motif search algorithm DME, we further identified the most highlyenriched RB1-binding motif in all conditions and cross-compare with the E2F3a motifs. Weconfirmed that RB1 and E2F3a co-occupy the mitotic regulator promoters by ChIP-PCR. IHCstudies of clinical OS specimens supported the clinical correlation between RB1/E2F3a andmitotic regulators. High mitotic regulator genes expression is correlated with poor prognosis. Ourresults demonstrated that the mitotic regulators are co-regulated by both RB1 and E2F3a andthey play roles in osteosarcomagenesis.Taken together, our findings demonstrated multiple OS-related phenotypes in human RB iPSC-derived OBs and RB1/E2F3a-regulating mitotic regulators can be a therapeutic vulnerability inRB1-mutant OS. Citation Format: Dandan Zhu, Jian Tu, Zijun Huo, An Xu, Mo-Fan Huang, Ying Liu, Yi-Hung Chen, Ruiying Zhao, Dung-Fang Lee. Dissecting the biology and therapeutic vulnerabilities of RB1-mutant osteosarcoma using hereditary retinoblastoma iPSCs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1616.
31
Fan, Li, Qingfei Pan, Wentao Yang, et al. "Abstract 5674: A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis." Cancer Research 82, no. 12_Supplement (2022): 5674. http://dx.doi.org/10.1158/1538-7445.am2022-5674.
Full textAbstract:
Abstract Background and Rationale: Hepatoblastoma (HB) is the most common pediatric liver cancer. Its predominant occurrence in very young children led us to investigating whether the neonatal liver provides a protumorigenic niche to HB development. Methods: HB development was compared between orthotopic transplantation models established in postnatal day 5 and 60 mice (P5Tx and P60Tx models). Single-cell RNA-sequencing was performed using tumor and liver tissues from both models and the top candidate cell types and genes identified are investigated for their roles in HB cell growth, migration, and survival. Results: We found that various HB cell lines including HepG2 cells were consistently and considerably more tumorigenic and metastatic in the P5Tx model than in the P60Tx models. Sc-RNAseq of the P5Tx and P60Tx HepG2 models revealed that the P5Tx tumor was more hypoxic and had a larger number of activated hepatic stellate cells (aHSCs) in the tumor-surrounding liver which express significantly higher levels of Cxcl1 than those from the P60Tx model. We found these differences were developmentally present in normal P5 and P60 liver. We showed that the Cxcl1/Cxcr2 axis mediated HB cell migration and was critical to HB cell survival under hypoxia. Treating HepG2 P60Tx model with recombinant CXCL1 protein induced intrahepatic and pulmonary metastasis and CXCR2 knockout in HepG2 cells abolished their metastatic potential in the P5Tx model. Lastly, we showed that in metastatic HB patient tumors there was a similar larger population of aHSCs in the tumor-surrounding liver than in localized tumors, and tumor hypoxia was uniquely associated with HB patient prognosis among pediatric cancers. Conclusion: We demonstrated that the neonatal liver provides a prometastatic niche to HB development via the Cxcl1/Cxcr2 axis. Citation Format: Li Fan, Qingfei Pan, Wentao Yang, Selene C. Koo, Cheng Tian, Liyuan Li, Meifen Lu, Anthony Brown, Bensheng Ju, John Easton, Sarangarajan Ranganathan, Soona Shin, Alexander Bondoc, Jun J. Yang, Jiyang Yu, Liqin Zhu. A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5674.
32
Ravindranathan, Sruthi, Passang Tenzin, Jian Ming Li, et al. "Abstract PO-072: Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy." Cancer Research 81, no. 22_Supplement (2021): PO—072—PO—072. http://dx.doi.org/10.1158/1538-7445.panca21-po-072.
Full textAbstract:
Abstract Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to immune checkpoint therapy largely due to a paucity of T cells within the tumor microenvironment (TME) and abundant immunosuppressive signaling pathways. In this study we show that human PDAC tumors over-express vasoactive intestinal peptide (VIP), an immunosuppressive neuropeptide that suppresses T cell effector properties and promotes the generation of regulatory T cells (Tregs). Therefore, we treated tumor-bearing mice with VIP receptor peptide antagonists and measured T cell homing, activation, and anti-tumor responses in preclinical murine models of PDAC. Pharmacological inhibition of VIP receptor (VIP-R) signaling using daily subcutaneous injections of peptide antagonists had no discernable toxicity in healthy and tumor-bearing mice. Treatment with VIP-R antagonists in combination with anti-PD-1 checkpoint blockade significantly decreased tumor burden, and improved survival in subcutaneous and orthotopic murine PDAC models. Combination therapy significantly enhanced T cell activation and proliferation and decreased frequencies of Tregs within the TME. Anti-tumor responses were T cell dependent, as the combination therapy failed to improve survival in CD4 or CD8 deficient mice using knock-out strains and antibody depletion. Furthermore, combination therapy significantly increased frequencies of tumor specific T cells (measured with a tetramer reagent) and provided protective immunity against tumor rechallenge. Combination therapy led to significant increases in the infiltration of adoptively transferred GFP+ T cells into PDAC tumors and decreased CXCR4 expression levels on T cells. Encouragingly, peptide-based VIP-R antagonists enhanced the in vitro activation of human T cells isolated from peripheral blood of PDAC patients. Human T cells cultured with VIP-R antagonists had increased proliferation, activation, and decreased proportions of T regs and exhausted T cells co-expressing PD-1, Tim-3 and Lag-3. Taken together, our findings show that VIP is a targetable mechanism of immune escape in PDAC. Inhibiting VIP receptor signaling improves T cell effector properties and synergistically improves anti-tumor responses to checkpoint inhibitors in mouse PDAC models. Additionally, as the VIP sequence is identical between human and mice, and since VIP-R antagonists have similar effects on human and murine T cells in culture, clinical translation is highly feasible. Citation Format: Sruthi Ravindranathan, Passang Tenzin, Jian Ming Li, Rohan Dhamsania, Michael Ware, Mohammad Zaidi, Shuhua Wang, Jingru Zhu, Maria Cardenas, Yuan Liu, Gaurav Joshi, Sanjeev Gumber, Brian Robinson, Anish Sen-Majumdar, Shanmuganathan Chandrakasan, Haydn Kissick, Alan Frey, Susan Thomas, Bassel El-Rayes, Gregory Lesinski, Edmund K. Waller. Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-072.
33
Lin, Cheng-Hung, Xiaoyin Zheng, Lei Wang, et al. "(Invited) Synchrotron X-Ray Nano-Tomography and Multimodal Studies of Li-Ion Batteries." ECS Meeting Abstracts MA2022-02, no. 2 (2022): 131. http://dx.doi.org/10.1149/ma2022-022131mtgabs.
Full textAbstract:
As batteries revolutionize all technological areas – from miniaturized electronic devices to electric vehicles and to large-scale energy storage, understanding the complex morphological, chemical and structural evolution and their interplays has been at the forefront of the research. Synchrotron X-ray characterization techniques provide insights into the electrochemical reactions and multiscale, multiphysics environments to address the fundamental mechanisms in these systems. The presentation will highlight the application of synchrotron X-ray analysis in two Li-ion battery systems, including both aqueous and non-aqueous systems. X-ray nano-tomography via transmission X-ray microscopy and spectroscopic imaging, complemented by other diffraction, spectroscopy and microscopy techniques, will be discussed. We will present how synchrotron X-ray nano-tomography and quantitative 3D morphological analysis were instrumental in revealing the dimensionality effect of conductive carbon fillers in LiNi 1/3Mn1/3Co1/3O2 (NMC111) cathode [1]. Additionally, we will discuss how a multimodal characterization approach offered insights when probing kinetics of water-in-salt aqueous batteries with thick, porous LiV3O8-LiMn2O4 electrodes [2, 3]. Through the morphological and chemical analyses, the work aims to facilitate the design of future advanced energy storage materials, as well as provide a novel characterization framework for studying a wider range of electrochemical systems. References: [1] "Dimensionality effect of conductive carbon fillers in LiNi 1/3Mn 1/3Co 1/3O 2 cathode", Cheng-Hung Lin, Zhengyu Ju, Xiaoyin Zheng, Xiao Zhang, Nicole Zmich, Xiaoyang Liu, Kenneth J. Takeuchi, Amy C.Marschilok, Esther S.Takeuchi, Mingyuan Ge, Guihua Yu, Yu-chen Karen Chen-Wiegart, Carbon (2021), DOI: https://doi.org/10.1016/j.carbon.2021.11.014 [2] "Probing Kinetics of Water-in-Salt Aqueous Batteries with Thick Porous Electrodes", Cheng-Hung Lin, Lei Wang, Steven T. King, Jianming Bai, Lisa M. Housel, Alison H. McCarthy, Mallory N. Vila, Hengwei Zhu, Chonghang Zhao, Lijie Zou, Sanjit Ghose, Xianghui Xiao, Wah-Keat Lee, Kenneth J. Takeuchi, Amy C. Marschilok, Esther S. Takeuchi, Mingyuan Ge, and Yu-chen Karen Chen-Wiegart, ACS Central Science (2021), DOI: 10.1021/acscentsci.1c00878 [3] "Systems-Level Investigation of Aqueous Batteries for Understanding the Benefit of Water-In-Salt Electrolyte by Synchrotron Nano-Imaging", Cheng-Hung Lin, Ke Sun, Mingyuan Ge, Lisa Housel, Alison McCarthy, Mallory Vila, Chonghang Zhao, Xianghui Xiao, Wah-Keat Lee, Kenneth J. Takeuchi, Esther S. Takeuchi, Amy C. Marschilok, Yu-chen Karen Chen-Wiegart, Science Advances (2020), DOI: 10.1126/sciadv.aay7129
34
Zhang, Jian, Yu Fang, Lei Sun, et al. "Abstract 5292: Investigating the potential relationship between BRAF mutations and tumor mutation burden (TMB) in lung cancer (LC)." Cancer Research 82, no. 12_Supplement (2022): 5292. http://dx.doi.org/10.1158/1538-7445.am2022-5292.
Full textAbstract:
Abstract BackgroundCurrently, BRAF inhibitors are primarily effective in LC patients with BRAF V600E mutation, while with limited benefit for patients with BRAF non-V600E mutation. Additionally, it is unclear whether immunotherapy is effective in LC patients with BRAF mutations, and the relationship between BRAF mutations and immune biomarkers, such as TMB, is also unclear. Here, we retrospectively investigated the relationship with BRAF mutation and TMB in Chinese LC patients.MethodsSamples were extracted from 3,136 our cohort samples of LC, which from OncoPanscan࣪ (Genetron Health) based sequencing of tissue. Because of the significantly different cohort characteristics, propensity score matching was used to resolve potential confounding by a nearest neighbor algorithm. The use of a multivariable logistic regression model to estimate the propensity score was based on age, sex, cancer type and detail panels. The samples after propensity score matching was used to investigate the relationship with TMB. ResultsIn our cohort, 171 samples had BRAF mutations and 2,965 samples had non-BRAF mutations. After propensity score analysis, 165 samples of BRAF mutations were screened with 165 paired samples of non-BRAF mutations.In the 165 samples of BRAF mutations, 83 samples of them had TMB information, while 83 samples of the 165 paired samples of non-BRAF mutations had TMB information. Patients with BRAF mutation had a higher median TMB than the patients with non-BRAF mutation (9.39 vs. 7.51 Muts/Mb, p=0.0545). Similarly, in these two groups, there was slightly higher ratio of samples with TMB ≥10muts/Mb (43.37% vs. 31.32%, P=0.0788). Among BRAF mutation group, when compared to BRAF V600E group (N=26), the median TMB was much higher in non-V600E group (N=57) (7.38 vs. 9.86 muts/Mb, P=0.0270). The proportion of TMB ≥10muts/Mb in BRAF non-V600E group was much higher than V600E group (49.12% vs. 30.77%, P=0.0094). Additionally, we analyzed the samples that had high TMB (TMB≥10 muts/Mb) and high PD-L1 (TPS≥50%). The BRAF mutation group had more proportion than non-BRAF mutation (14.46% vs.6.02%, p=0.0593), and the BRAF non-V600E group was higher than BRAF V600E group (15.79% vs. 11.54%, P=0.4150).ConclusionsCompared with non-BRAF mutation, BRAF mutation was associated with higher TMB, and it was also higher in BRAF non-V600E than BRAF V600E. These results suggested that patients with driver mutation of BRAF V600E had lower TMB and they always had good response to BRAF inhibitors. While LC patients with BRAF non-V600E always with higher TMB, thus, they may be more suitable for immunotherapy. However, more clinical research are needed to evaluate the effectiveness of immunotherapy. Citation Format: Jian Zhang, Yu Fang, Lei Sun, Hongling Yuan, Mao Shang, Xiaoyan Zhang, Honglin Zhu, Tonghui Ma. Investigating the potential relationship between BRAF mutations and tumor mutation burden (TMB) in lung cancer (LC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5292.
35
Mao, Lili, Jun Guo, Lingjun Zhu, et al. "Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study." Cancer Research 82, no. 12_Supplement (2022): CT519. http://dx.doi.org/10.1158/1538-7445.am2022-ct519.
Full textAbstract:
Abstract Purpose: No targeted therapy has been approved for NRAS-mutant melanoma. We evaluated the safety and tolerability and determined the recommended phase 2 dose (RP2D) of FCN-159, a selective MEK1/2 inhibitor, in patients with NRAS-mutant advanced melanoma. Methods: This single-arm, open-label, dose-escalation, phase 1A study in China (NCT03932253) enrolled patients with unresectable stage III/IV melanoma harboring NRAS mutations. Patients received FCN-159 in doses escalating from 0.2 mg until the maximum tolerated dose (MTD). Oral FCN-159 was given once in the single-dose period and once daily (QD) in 28-day cycles in the continuous-dose period. The primary endpoint was the incidence of dose-limiting toxicity (DLT). Results: As of September 16, 2021, 33 patients were enrolled and received 0.2-15 mg FCN-159. All patients had received systemic treatments. One DLT event (grade 3 folliculitis) occurred in the 15 mg group, and no DLT occurred at other dose levels; MTD was defined as 15 mg QD. Grade ≥3 treatment-emergent adverse events (TEAEs) deemed related to FCN-159 were reported in 5 (15.2%) patients across dose levels; stomatitis (2; 6.1%) was the most common. No FCN-159-related TEAEs were serious or led to treatment discontinuation. Among 21 patients assigned to doses ≥6 mg, 4 had investigator-confirmed objective responses (objective response rate, 19.0%; 95% confidence interval [CI], 5.4-41.9); all were partial responses (Table). Median DOR was 4.8 months (95% CI, 2.8-NE). Seven patients had SD (CBR, 52.4%; 95% CI, 29.8-74.3). Median progression-free survival was 3.8 months (95% CI, 1.8-5.6). FCN-159 12 mg QD was determined to be the RP2D per assessment of safety, antitumor activity, and pharmacokinetic data. Conclusion: FCN-159 was well tolerated and showed antitumor activity in patients with NRAS-mutant advanced melanoma. FCN-159 12 mg QD as a treatment for NRAS-mutant advanced melanoma warrants future investigation. Tumor response was assessed by the investigators according to Response Evaluation Criteria in Solid Tumors version 1.1.BOR, best overall response; CBR, clinical benefit rate; CR, complete response; DOR, duration of response; NA, not applicable; NE, not evaluable; NR, not reached; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease. Table. Confirmed best overall response 6 mg(n = 5) 8 mg(n = 4) 12 mg(n = 6) 15 mg(n = 6) Total(N = 21) Confirmed BOR, n (%) CR 0 0 0 0 0 PR 2 (40.0) 1 (25.0) 0 1 (16.7) 4 (19.0) SD 1 (20.0) 1 (25.0) 3 (50.0) 2 (33.3) 7 (33.3) PD 2 (40.0) 2 (50.0) 1 (16.7) 2 (33.3) 7 (33.3) NE 0 0 2 (33.3) 1 (16.7) 3 (14.3) ORR, n (%), 95% CI 2 (40.0), 5.3–85.3 1 (25.0), 0.6–80.6 0 1 (16.7), 0.4–64.1 4 (19.0), 5.4–41.9 CBR, n (%), 95% CI 3 (60.0), 14.7–94.7 2 (50.0), 6.8–93.2 3 (50.0), 11.8–88.2 3 (50.0), 11.8–88.2 11 (52.4), 29.8–74.3 Median DOR (95% CI), months 4.8 (2.8–NE) NR (NE–NE) NA NR (NE–NE) 4.8 (2.8–NE) Citation Format: Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Jian Zhang, Ai-min Hui, Zhuli Wu, Yuchen Yang, Han Zhao, Yiqian Jiang, Lu Si. FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT519.
36
Dybov, Vladislav А., Dmitrii V. Serikov, Galina S. Ryzhkova та Aleksey I. Dontsov. "Роста и субструктура пленок ниобата лития". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 1 (2019): 51–59. http://dx.doi.org/10.17308/kcmf.2019.21/716.
Full textAbstract:
Проведены исследования начальных стадий роста пленок ниобата лития на Si в процессе ВЧМР, исследовано влияние условий ВЧМР и последующих обработок (ТО, ИФО, БТО) на структуру, субструктуру и ориентацию получаемых покрытий. Установлено, что начальные стадии роста пленок ниобата лития в процессе ВЧМР на подогретой до 550 °С Si подложке характеризуются островковым зарождением кристаллитов и последующей их коалесценцией. Показана возможность управления текстурой пленок ниобата лития в процессе ВЧМР в условиях воздействия плазмы ВЧ-разряда, путем изменения состава рабочего газа. Показан эффект ИФО в кристаллизации аморфных пленок состава ниобата лития, заключающийся в формировании однофазной нанокристаллической пленки ниобата лития, в процессе обработки на воздухе.
 
 ИСТОЧНИК ФИНАНСИРОВАНИЯ
 Исследование выполнено при финансовой поддержке РФФИ, проект № 18-33-00836.
 
 
 ЛИТЕРАТУРА
 
 Lu Y, Dekker P., Dawes J.M. Journal of Crystal Growth, 2009, vol. 311, pp. 1441-1445. https://doi.org/10.1016/j.jcrysgro.2008.12.035
 Poghosyan A. R., Guo R., Manukyan A. L., Grigoryana S. G. SPIE, 2007, vol. 6698, pp. 1-5. https://doi.org/10.1117/12.734353
 Kadota M., Suzuki Y., Ito Y. Japanese Journal of Applied Physics, 2011, vol. 50, pp. 1-5. DOI: https://doi.org/10.1143/jjap.50.07hd10
 Hao L., Li Y., Zhu J., Wu Z., Wang J., Liu X., Zhang W. Journal of Alloys and Compounds, 2014, vol. 599, pp. 108-113. https://doi.org/10.1016/j.jallcom.2014.02.078
 Gupta V., Bhattacharya P., Yuzyuk Yu. I., Katiyar R. S. Mater. Res., 2004, vol. 19, N 8, pp. 2235-2239. https://doi.org/10.1557/jmr.2004.0322
 Tan S., Gilbert T., Hung C.-Y., and Schlesinger T. E. Phys. Lett., 1996, vol. 68, p. 2651. https://doi.org/10.1063/1.116270 
 Shih W.-C., Sun X.-Y. Physica B: Condensed Matter, 2010, vol. 405, no. 6, pp. 1619–623. https://doi.org/10.1016/j.physb.2009.12.054
 Barinov S. M., Belonogov E. K., Ievlev V. M., et al. DokladyPhysical Chemistry, 2007, vol. 412, no. 1, pp. 15-18. https://doi.org/10.1134/s0012501607010058 
 Hansen P. J., Terao Y., Wu Y., York R. A., Mishra U. K., Speck J. S. Vac. Sci. Technol., 2005, vol. 23, № 1, pp. 162-167. https://doi.org/10.1116/1.1850106
 Sumets M., Ievlev V., Kostyuchenko A., Vakhtel V., Kannykin S., Kobzev A. Thin Solid Films, 2014, vol. 552, pp. 32–38. https://doi.org/10.1016/j.tsf.2013.12.005
 Seok-Won Choi, et al. The Korean Journal of Ceramics, 2000, vol. 6, no. 20, pp. 138-142.
 Ievlev V. M., Soldatenko S. A., Kushhev S. B., Gorozhankin Ju. V. Inorganic Materials, 2008, vol. 44, no. 7, pp. 705-712. https://doi.org/10.1134/s0020168508070066
 Ievlev V. M., Turaeva T. L., Latyshev A. N., et al. The Physics of Metals and Metallography, 2007, vol. 103, no. 1, pp. 58-63. https://doi.org/10.1134/s0031918x07010073 
37
Budanov, Alexander V., Yury N. Vlasov, Gennady I. Kotov, Evgeniy V. Rudnev та Pavel I. Podprugin. "Формирование тонких пленок соединений Cu2SnS3 и Cu2SnSe3". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 1 (2019): 24–29. http://dx.doi.org/10.17308/kcmf.2019.21/713.
Full textAbstract:
Показана возможность синтеза соединений Cu2SnS3 и Cu2SnSe3 на стеклянных подложках путём отжига в парах халькогена тонкой металлической плёнки сплава Cu:Sn = 2:1 в вакуумной графитовой камере типа квазизамкнутого объёма. Методом рентгеновской дифракции установлено, что полученные плёнки халькогенидов имеют подобную сфалериту кристаллическую структуру. Для кубической модификации Cu2SnS3 и Cu2SnSe3 преимущественными плоскостями отражений являются (111), (220) и (311). Элементный состав плёнок соответствует стехиометрии соединений Cu2SnS3 и Cu2SnSe3. Методом ИК-спектроскопии определены энергии активации прямозонных переходов для Cu2SnS3 – 0.96 eV, а для Cu2SnSe3 – 0.70 eV.
 
 ИСТОЧНИК ФИНАНСИРОВАНИЯ
 Работа выполнена при финансовой поддержке гранта РФФИ № 18-32-00971 – мол_а.
 
 ЛИТЕРАТУРА
 
 Milichko V. A., Shalin A. S., Mukhin I. S., et al. Usp., 2016, vol. 59, pp. 727–772. https://doi.org/10.3367/ufne.2016.02.037703
 Wesley Herche. Renewable and Sustainable Energy Reviews, 2017, vol. 77, pp. 590-595. https://doi.org/10.1016/j.rser.2017.04.028
 Rujun Suna, Daming Zhuang, Ming Zhao, et al. Solar Energy Materials and Solar Cells, 2018, vol. 174, pp. 42–49. https://doi.org/10.1016/j.solmat.2017.08.011
 Orletskii I. G., Mar’yanchuk P. D., Solovan M. N., et al. Physics of the Solid State, 2016. vol. 58, no. 5, pp. 1058-1064. https://doi.org/10.1134/s1063783416050188 
 Ren Y. Acta Universitatis Upsaliensis, Uppsala, 2017, 85 p. URL: https://uu.diva-portal.org/smash/get/diva2:1072439/FULLTEXT01.pdf
 Lokhande A. C. Solar Energy Materials and Solar Cells, August 2016, vol. 153, pp. 84-107. https://doi.org/10.1016/j.solmat.2016.04.003
 Shelke H. D., Lokhande A. C., Patil A. M., et al. Surfaces and Interfaces, 2017, vol. 9, pp. 238-244. https://doi.org/10.1016/j.surfin.2017.08.006
 Orletskii I. G., Solovan M. N., Pinna F., et al. Physics of the Solid State. 2017, vol. 59, no. 4, pp. 801-807. https://doi.org/10.1134/s1063783417040163
 Mingrui He. Journal of Alloys and Compounds, April 2017, vol. 701, pp. 901-908. https://doi.org/10.1016/j.jallcom.2017.01.191 
 Pin-Wen, GuanShun-Li Shang, Greta Lindwall. Solar Energy, 2017, vol. 155, pp. 745-757. https://doi.org/10.1016/j.solener.2017.07.017 
 Ju Yeon Lee. Solar Energy, 2017, vol. 145, pp. 27-32. https://doi.org/10.1016/j.solener.2016.09.041
 Subbotina, O. Y., Kishkoparov N. V., Frishberg I. V. High Temperature, 1999, vol. 37, no. 2, pp. 198–203. URL: http://www.mathnet.ru/php/archive.phtml?wshow=paper&jrnid=tvt&paperid=2266&option_lang=rus (in Russ.)
 Budanov A. V., Vlasov Yu. N., Grechkina M. V., et al. Condensed Matter and Interphases, 2016, vol. 18, no. 4, pp. 481–486. URL: http://www.kcmf.vsu.ru/resources/t_18_4_2016_004.pdf (in Russ.)
 Zhang, Huang L. L., Zhu X. G., et al. Scripta Materialia, 2019, vol. 159, pp. 46–50. https://doi.org/10.1016/j.scriptamat.2018.09.010
 Lukashev P., Lambrecht W. R. L., Kotani T., Schilfgaarde M. Rev. B: Condens. Matter Mater. Phys., 2007, vol. 76, p. 195202. https://doi.org/10.1103/physrevb.76.195202
 
38
Wu, Jiong, Zhenzhen Liu, Hongjian Yang, et al. "Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study." Cancer Research 82, no. 4_Supplement (2022): PD8–08—PD8–08. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd8-08.
Full textAbstract:
Abstract Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine have shown clinically and statistically meaningful progression free survival and overall survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer in phase 3 study. We compared the efficacy and safety of adding pyrotinib to trastuzumab and docetaxel vs placebo, trastuzumab and docetaxel as neoadjuvant treatment in women with HER2-positive early or locally advanced breast cancer (ABC) in this randomized, double-blind, multicenter, phase 3 study. Methods: Treatment naive patients with HER2-positive early or locally ABC (T2-3, N0-3, M0) were randomly assigned (1:1) to pyrotinib arm receiving 4 neoadjuvant cycles of pyrotinib (400 mg po qd, d1-21, q3w), trastuzumab (8 mg/kg iv, cycle 1 d1, then 6 mg/kg d1 q3w) and placebo arm with docetaxel (100 mg/m2 iv d1, q3w) or placebo, trastuzumab and docetaxel. Randomization was done via a centralized interactive web-response system and stratified by primary tumor size (&gt;2 cm and ≤5cm, or &gt;5cm) and hormone receptor status (ER positive and/or PR positive, or negative for both). After surgery, patients received 3 cycles of intravenous fluorouracil, epirubicin, and cyclophosphamide followed by anti-cancer treatment (anti-HER2 therapy, radiotherapy, or endocrine therapy) at physicians’ discretion in accordance with clinical practice guidelines. The primary endpoint was total pCR rate (tpCR; defined as absence of any residual invasive cancer in the breast and lymph nodes [ypT0/is, ypN0]), assessed by an independent review committee (IRC). This study is registered with ClinicalTrials.gov, number NCT03588091. The data cutoff date was April 30, 2021. Results: Between July 23, 2018 and January 8, 2021, a total of 355 patients were randomized (pyrotinib arm, n=178; and placebo arm, n=177; mean [SD] age, 48.8 [9.4] years). Baseline demographics and disease characteristics were well balanced. In the full analysis set, IRC-assessed tpCR rates were 41.0% (73 of 178) in the pyrotinib arm and 22.0% (39 of 177) in the placebo arm (difference, 19.0% [95% CI, 9.5%-28.4%]; one-sided P&lt;0.0001). The local pathologist-assessed tpCR rates were 44.4% (79 of 178) and 24.3% (43 of 177) in the pyrotinib arm and the placebo arm, respectively. Incidence of grade ≥3 adverse events (AEs) was 71.3% (127 of 178) in the pyrotinib arm and 37.3% (66 of 177) in the placebo arm. Of the most-common grade ≥3 AEs (≥5% of patients in either arm), the incidences of diarrhea (79 of 178 [44.4%] vs 9 of 177 [5.1%]), decreased WBC count (29 of 178 [16.3%] vs 24 of 177 [13.6%]), vomiting (23 of 178 [12.9%] vs 2 of 177 [1.1%]), anemia (11 of 178 [6.2%] vs 2 of 177 [1.1%]), and hypokalemia (9 of 178 [5.1%] vs 0) were higher in the pyrotinib arm compared with the placebo arm. Grade 3 diarrhea occurred mainly during the first treatment cycle and decreased in the second cycle and thereafter. No grade 4 or 5 diarrheas occurred. The median duration per grade 3 episode was 2.0 days and median cumulative duration of grade 3 episodes was 4.0 days. Only 1 patient (1 of 178 [0.6%]) in the pyrotinb arm experienced diarrhea-related discontinuation. Serious AEs were reported in 14.6% of patients (26 of 178) in the pyrotinib arm and 6.8% of patients (12 of 177) in the placebo arm. Conclusions: Pyrotinib, trastuzumab, and docetaxel as neoadjuvant treatment achieved a statistically significant and clinically meaningful improvement in IRC-assessed tpCR rate for patients with HER2-positive early or locally ABC compared with placebo, trastuzumab, and docetaxel, with an acceptable and manageable safety profile. These findings support pyrotinib, trastuzumab, and docetaxel as a new neoadjuvant treatment option in this patient population. Citation Format: Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Tao Zhang, Jianjun Zou. Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD8-08.
39
Seredin, Pavel V., Dmitry L. Goloshchapov, Kirill A. Nikitkov, Vladimir M. Kashkarov, Yury A. Ippolitov та Vongsvivut Jitraporn (Pimm). "Применение синхротронной ИК-микроспектроскопии для анализа интеграции биомиметических композитов с нативной твердой тканью зуба человека". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 2 (2019): 262–77. http://dx.doi.org/10.17308/kcmf.2019.21/764.
Full textAbstract:
В данной работе продемонстрирована возможность применения ИК-микроспектроскопии для многомерной визуализации и анализа интеграции с нативными твердыми тканями зуба человека нового поколения биомиметических материалов, воспроизводящих минералорганический комплекс эмали и дентина.На основе ИК-картирования интенсивности конкретной функциональной молекулярной группы с использованием синхротронного излучения найдены и визуализированы характеристические особенности биомиметического переходного слоя в межфазной области эмаль/стоматологический материал и определено расположение функциональных групп, отвечающих процессам интеграции биомиметического композита
 
 
 REFERENCES
 
 Rohr N., Fischer J. Tooth surface treatment strategies for adhesive cementation // The Journal of Advanced Prosthodontics, 2017, v. 9(2), pp. 85–92. https://doi.org/10.4047/jap.2017.9.2.85
 Pereira C. N. de B., Daleprane B., Miranda G. L. P. de, Magalhães C. S. de, Moreira A. N. Ultramorphology of pre-treated adhesive interfaces between self-adhesive resin cement and tooth structures // Revista de Odontologia da UNESP, 2017, v. 46(5), pp. 249–254. https://doi.org/10.1590/1807-2577.04917
 Temel U. B., Van Ende A., Van Meerbeek B., Ermis R. B. Bond strength and cement-tooth interfacial characterization of self-adhesive composite cements //American Journal of Dentistry, 2017, v. 30(4), pp. 205–211.
 Watson T. F., Atmeh A. R., Sajini S., Cook R. J., Festy F. Present and future of glass-ionomers and calcium-silicate cements as bioactive materials in dentistry: Biophotonics-based interfacial analyses in health and disease // Dental Materials, 2014, v. 30(1), pp. 50–61. https://doi.org/10.1016/j.dental.2013.08.202
 Pontes D. G., Araujo C. T. P., Prieto L. T., de Oliveira D. C. R. S., Coppini E. K., Dias C. T. S., Paulillo L. A. M. S. Nanoleakage of fi ber posts luted with different adhesive strategies and the effect of chlorhexidine on the interface of dentin and self-adhesive cements // General Dentistry, 2015, v. 63(3), pp. 31–37. PMID: 25945761
 Teaford M. F., Smith M. M., Ferguson W. J. Development, Function and Evolution of Teeth. Cambridge University Press, 2007, 328 p.
 Dorozhkin S. V. Hydroxyapatite and Other Calcium Orthophosphates: Bioceramics, Coatings and Dental Applications [Hardcover]. Nova Science Publishers, Inc New York, 2017, 462 p. URL: https://istina.msu.ru/publications/book/58538935/
 Uskoković V. Biomineralization and biomimicry of tooth enamel. Non-Metallic Biomaterials for Tooth Repair and Replacement. Elsevier, 2013, pp. 20–44. URL:http://linkinghub.elsevier.com/retrieve/pii/B9780857092441500021
 Niu L., Zhang W., Pashley D. H., Breschi L., Mao J., Chen J., Tay F. R. Biomimetic remineralization of dentin // Dental Materials, 2014, v. 30(1), pp. 77–96. https://doi.org/10.1016/j.dental.2013.07.013
 Cao C., Mei, Li Q., Lo E., Chu C. Methods for Biomimetic Mineralisation of Human Enamel: A Systematic Review // Materials, 2015, v. 8(6), pp. 2873–2886. https://doi.org/10.3390/ma8062873
 Chen L., Yuan H., Tang B., Liang K., Li J. Biomimetic remineralization of human enamel in the presence of polyamidoamine dendrimers in vitro // Caries Research, 2015, v. 49(3), pp. 282–290. https://doi.org/10.1159/000375376
 Seredin P. V., Goloshchapov D. L., Gushchin M. S., Ippolitov Y. A., Prutskij T. The importance of the biomimetic composites components for recreating the optical properties and molecular composition of intact dental tissues. // Journal of Physics: Conference Series, 2017, v. 917(4), pp. 042019. https://doi.org/10.1088/1742-6596/917/4/042019
 Xia Z. Biomimetic Principles and Design of Advanced Engineering Materials. John Wiley & Sons, 2016, 321 p.
 Dorozhkin S. V. Self-Setting Calcium Orthophosphate Formulations: Cements, Concretes, Pastes and Putties // International Journal of Materials and Chemistry, 2012, v. 1(1), pp. 1–48. https://doi.org/10.5923/j.ijmc.20110101.01
 Li H., Gong M., Yang A., Ma J., Li X., Yan Y. Degradable biocomposite of nano calcium-defi cient hydroxyapatite-multi(amino acid) copolymer // International Journal of Nanomedicine, 2012, v. 7, pp. 1287–1295. https://doi.org/10.2147/IJN.S28978
 Ruan Q., Zhang Y., Yang X., Nutt S., Moradian-Oldak J. An amelogenin–chitosan matrix promotes assembly of an enamel-like layer with a dense interface// Acta Biomaterialia, 2013, v. 9(7), pp. 7289–7297. https://doi.org/10.1016/j.actbio.2013.04.004
 Yao, Shao H., Zhang Q. Development and Characterization of a Novel Amorphous Calcium Phosphate/Multi (Amino Acid) Copolymer Composite for Bone Repair // Journal of Biomaterials and Tissue Engineering, 2015, v. 5(5), pp. 387–390. https://doi.org/10.1166/jbt.2015.1321
 Melo M. A. S., Weir M. D., Rodrigues L. K. A., Xu H. H. K. Novel calcium phosphate nanocomposite with caries-inhibition in a human in situ model // Dental Materials, 2013, v. 29(2), pp. 231–240. https://doi.org/10.1016/j.dental.2012.10.010
 Wu X.-T., Mei M., Li Q.-L., Cao C., Chen-L., Xia R., Zhang Z.-H., Chu C. A Direct Electric Field-Aided Biomimetic Mineralization System for Inducing the Remineralization of Dentin Collagen Matrix // Materials, 2015, v. 8(12), pp. 7889–7899. https://doi.org/10.3390/ ma8115433
 Barghamadi H., Atai M., Imani M., Esfandeh M. Effects of nanoparticle size and content on mechanical properties of dental nanocomposites: experimental versus modeling // Iranian Polymer Journal, 2015, v. 24. (10), pp. 837–848. https://doi.org/10.1007/s13726-015-0369-5
 Wang H., Xiao Z., Yang J., Lu D., Kishen A., Li Y., Chen Z., Que K., Zhang Q., Deng X., Yang X., Cai Q., Chen N., Cong C., Guan B., Li T., Zhang X. Oriented and Ordered Biomimetic Remineralization of the Surface of Demineralized Dental Enamel Using HAP@ ACP Nanoparticles Guided by Glycine // Scientifi c Reports, 2017, v. 7(1), рр. 1-13. https://doi.org/10.1038/srep40701
 Wu X., Zhao X., Li Y., Yang T., Yan X., Wang K. In situ synthesis carbonated hydroxyapatite layers on enamel slices with acidic amino acids by a novel twostep method // Materials Science & Engineering. C, Materials for Biological Applications, 2015, v. 54, pp. 150–157. httsp://doi.org/10.1016/j.msec.2015.05.006
 Aljabo A., Abou Neel E. A., Knowles J. C., Young A. M. Development of dental composites with reactive fi llers that promote precipitation of antibacterial-hydroxyapatite layers // Materials Science and Engineering: C, 2016, v. 60, pp. 285–292. https://doi.org/10.1016/j.msec.2015.11.047
 Wang P., Liu P., Peng H., Luo X., Yuan H., Zhang J., Yan Y. Biocompatibility evaluation of dicalcium phosphate/calcium sulfate/poly (amino acid) composite for orthopedic tissue engineering in vitro and in vivo // Journal of Biomaterials Science. Polymer Edition, 2016, v. 27(11), pp. 1170–1186. https://doi.org/10.1080/09205063.2016.1184123
 Lübke A., Enax J., Wey K., Fabritius H.-O., Raabe D., Epple M. Composites of fl uoroapatite and methylmethacrylate-based polymers (PMMA) for biomimetic tooth replacement // Bioinspiration & Biomimetics, 2016, v. 11(3), pp. 035001. https://doi.org/10.1088/1748-3190/11/3/035001
 Sa Y., Gao Y., Wang M., Wang T., Feng X., Wang Z., Wang Y., Jiang T. Bioactive calcium phosphate cement with excellent injectability, mineralization capacity and drug-delivery properties for dental bio- mimetic reconstruction and minimum intervention therapy. RSC Advances, 2016, v. 6(33), pp. 27349–27359. https://doi.org/10.1039/C6RA02488B
 Adachi T., Pezzotti G., Yamamoto T., Ichioka H., Boffelli M., Zhu W., Kanamura N. Vibrational algorithms for quantitative crystallographic analyses of hydroxyapatite-based biomaterials: II, application to decayed human teeth // Analytical and Bioanalytical Chemistry, 2015, v. 407(12), pp. 3343–3356. https://doi.org/10.1007/s00216-015-8539-z
 Mitić Ž., Stolić A., Stojanović S., Najman S., Ignjatović N., Nikolić G., Trajanović M. Instrumental methods and techniques for structural and physicochemical characterization of biomaterials and bone tissue: A review // Materials Science and Engineering: C, 2017, v. 79, pp. 930–949. https://doi.org/10.1016/j.msec.2017.05.127
 Optical spectroscopy and computational methods in biology and medicine / Ed. by Barańska M., Dordrecht: Springer, 2014, 540 p. URL: http://link.springer.com/10.1007/978-94-007-7832-0
 Hędzelek W., Marcinkowska A., Domka L., Wachowiak R. Infrared Spectroscopic Identifi cation of Chosen Dental Materials and Natural Teeth // Acta Physica Polonica A, 2008, v. 114(2), pp. 471–484. https://doi.org/10.12693/APhysPolA.114.471
 Vongsvivut J., Perez-Guaita D., Wood B. R., Heraud P., Khambatta K., Hartnell D., Hackett M. J., Tobin M. J. Synchrotron macro ATR-FTIR microspectroscopy for high-resolution chemical mapping of single cells // The Analyst, 2019, v. 144(10), pp. 3226–3238. https://doi.org/10.1039/c8an01543k
 Seredin P., Goloshchapov D., Ippolitov Y., Vongsvivut P. Pathology-specifi c molecular profi les of saliva in patients with multiple dental caries—potential application for predictive, preventive and personalised medical services // EPMA Journal, 2018, v. 9(2), pp. 195–203. https://doi.org/10.1007/s13167-018-0135-9
 Dusevich V., Xu C., Wang Y., Walker M. P., Gorski J. P. Identifi cation of a protein-containing enamel matrix layer which bridges with the dentine–enamel junction of adult human teeth // Archives of Oral Biology, 2012, v. 57(12), pp. 1585–1594. https://doi.org/10.1016/j.archoralbio.2012.04.014
 Seredin P. V., Kashkarov V. M., Lukin A. N., Goloshchapov D. L., Ippolitov Y. A. Research Hydroxyapatite Crystals and Organic Components of Hard Tooth Tissues Affected by Dental Caries Using Ftir-Microspectroscopy and Xrd-Microdiffraction // Condensed Matter and Interphases, 2013, v. 15(3), с. 224–231. URL: http://www.kcmf.vsu.ru/resources/t_15_3_2013_002.pdf
 Fattibene P., Carosi A., Coste V. D., Sacchetti A., Nucara A., Postorino P., Dore P. A comparative EPR, infrared and Raman study of natural and deproteinated tooth enamel and dentin // Physics in Medicine and Biology, 2005, v. 50(6), pp. 1095. https://doi.org/10.1088/0031-9155/50/6/004
 Seredin P., Goloshchapov D., Kashkarov V., Ippolitov Y., Bambery K. The investigations of changes in mineral–organic and carbon–phosphate ratios in the mixed saliva by synchrotron infrared spectroscopy // Results in Physics, 2016, v. 6, pp. 315–321. https://doi.org/10.1016/j.rinp.2016.06.005
 Goloshchapov D. L., Kashkarov V. M., Rumyantseva N. A., Seredin P. V., Lenshin A. S., Agapov B. L., Domashevskaya E. P. Synthesis of nanocrystalline hydroxyapatite by precipitation using hen’s eggshell // Ceramics International, 2013, v. 39(4), pp. 4539–4549. https://doi.org/10.1016/j.ceramint.2012.11.050
 Goloshchapov D. L., Lenshin A. S., Savchenko D. V., Seredin P.V. Importance of defect nanocrystalline calcium hydroxyapatite characteristics for developing the dental biomimetic composites // Results in Physics, 2019, v. 13, pp. 102158. https://doi.org/10.1016/j.rinp.2019.102158
 Nanci A. Ten Cate’s Oral Histology: Development, Structure, and Function. 8th ed., Elsevier Health Sciences, 2013, 400 p.
 Ippolitov Ju. A. Vozmozhnost’ povyshenija biologicheskoj tropnosti svetootverzhdaemoj bondingovoj sistemy dlja adgezii tverdyh tkanej zuba k plombirovochnomu material [The possibility of increasing the biological tropism of the lightcuring bonding system for adhesion of hard tooth tissues to the filling material]. Volgogradskij nauchno-medicinskij zhurnal, 2010, v. 4 (28), pp. 31–34. URL: https://www.volgmed.ru/uploads/journals/articles/1293119124-bulletin-2010-4-815.pdf
 Seredin P., Goloshchapov D., Prutskij T., Ippolitov Y. Phase Transformations in a Human Tooth Tissue at the Initial Stage of Caries. PLoS ONE, 2015, v. 10(4), pp. 1–11. https://doi.org/10.1371/journal.pone.0124008
 Seredin P. V., Goloshchapov D. L., Prutskij T., Ippolitov Yu. A. A Simultaneous Analysis of Microregions of Carious Dentin by the Methods of Laser- Induced Fluorescence and Raman Spectromicroscopy. Optics and Spectroscopy, 2018, v. 125(5), pp. 803–809. https://doi.org/10.1134/S0030400X18110267
 Seredin P. V., Goloshchapov D. L., Prutskij T., Ippolitov Yu. A. Fabrication and characterisation of composites materials similar optically and in composition to native dental tissues. Results in Physics, 2017, v. 7, pp. 1086–1094. https://doi.org/10.1016/j.rinp.2017.02.025
40
He, Min, Benlong Yang, Jiong Wu, et al. "Abstract P5-18-10: Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study." Cancer Research 82, no. 4_Supplement (2022): P5–18–10—P5–18–10. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-18-10.
Full textAbstract:
Abstract Background: A dose relationship may exist for both antitumor activity and toxicity of docetaxel in breast cancer (BC) patients, while 86% grade 4 neutropenia and 12% febrile neutropenia (FN) were reported when pretreated advanced breast cancer (ABC) patients received 100 mg/m2 docetaxel monotherapy without hematopoietic support. PHEDRA was a randomized, double-blind, multicenter, phase 3 study comparing the efficacy and safety of adding pyrotinib to trastuzumab and docetaxel as neoadjuvant treatment in women with HER2+ early or locally ABC (ClinicalTrials.gov: NCT03588091). We conducted this exploratory analysis to evaluate the effectiveness of mecapegfilgrastim, a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), as primary prophylaxis for neoadjuvant chemotherapy-induced neutropenia in BC patients. Methods: Patients with HER2-positive early or locally ABC were randomly assigned (1:1) to pyrotinib arm receiving 4 neoadjuvant cycles of docetaxel (100 mg/m2 iv d1 q3w), trastuzumab (8 mg/kg iv, cycle 1 d1, then 6 mg/kg d1 q3w), and pyrotinib (400 mg po qd, d1-21, q3w) or placebo arm with placebo, trastuzumab and docetaxel. Per protocol, patients were required to receive a single, 6-mg fixed dose of mecapegfilgrastim on Day 2 of each cycle. Other G-CSF was permitted if mecapegfilgrastim was unavailable at the local center or patients occurred mecapegfilgrastim intolerance. The incidence of neutropenia, FN, time to first neutropenia onset, duration per neutropenia event and cumulative neutropenia duration during neoadjuvant treatment period; and the incidences of grade 3/4 neutropenia, FN and decreased WBC count in Cycle 1 to 4 (C1-4) were presented. The data cutoff date was April 30, 2021. Results: Between July 23, 2018 and January 8, 2021, 355 patients were randomized (pyrotinib arm, n=178; placebo arm, n=177). Among them, 291 (82.0%) patients received a single, 6-mg fixed dose of mecapegfilgrastim in Cycle 1 and 270 (76.1%) patients received mecapegfilgrastim in each of the 4 cycles. Grade 3/4 neutropenia was reported in 33 (18.5%) patients in the pyrotinib arm and 36 (20.3%) patients in the placebo arm. Five (2.8%) patients in the pyrotinib arm and 2 (1.1%) patients in the placebo arm developed FN (5 FN occurred in C1; 2 FN occurred in C2). Median duration of grade 3/4 neutropenia was 3 days in the pyrotinib group and 3 days in the placebo group. Median cumulative duration of grade 3/4 neutropenia was 4 days and 3 days in the pyrotinib group and the placebo group, respectively. Grade 3/4 neutropenia mainly occurred during the first cycle of treatment for both pyrotinib (13.5%) and placebo arm (15.8%), reduced in the second cycle (5.9% vs 4.0%) and thereafter (C3: 1.8% vs 3.4%; C4: 2.4% vs 1.7%). Similar trends were observed for grade 3/4 WBC count decreased in Cycle 1 to 4. No grade 4 infection occurred. Overview of neutropenia, FN and WBC count decreased was summarized in Table 1. Consistent findings were observed in 291 mecapegfilgrastim treated patients. Conclusion: The exploratory analysis demonstrated 6-mg fixed dose of mecapegfilgrastim was effective when administrated as primary prophylaxis for neoadjuvant chemotherapy-induced neutropenia, which could be considered as a new treatment option for its advantage of once-per-cycle dosing and convenient dose management. Table 1.Overview of neutropenia, febrile neutropenia and WBC count decrease during neoadjuvant treatment period.Docetaxel+Trastuzumab+Pyrotinib(N=178)Docetaxel+Trastuzumab+Placebo (N=177)All randomized patients(N=355)Neutropenia, n (%)Any grade57 (32.0)54 (30.5)111 (31.3)Grade 16 (3.4)5 (2.8)11 (3.1)Grade 218 (10.1)13 (7.3)31 (8.7)Grade 315 (8.4)20 (11.3)35 (9.9)Grade 418 (10.1)16 (9.0)34 (9.6)Median time to first onset (IQR), days7 (6-63)6 (6-49)7 (6-53)Median duration per grade 3 or higher neutropenia, days (range)3 (1-16)3 (2-12)3 (1-16)Median cumulative duration of grade 3 or higher neutropenia, days (range)4 (2-16)3 (2-14)3 (2-16)FN, n (%)5 (2.8)2 (1.1)7 (2.0)Grade 3 or higher neutropenia, n (%) *Cycle 124 (13.5)28 (15.8)52 (14.6)Cycle 210 (5.9)7 (4.0)17 (4.9)Cycle 33 (1.8)6 (3.4)9 (2.6)Cycle 44 (2.4)3 (1.7)7 (2.1)Grade 3 or higher FN, n (%) *Cycle 12 (1.1)2 (1.1)4 (1.1)Cycle 22 (1.2)02 (0.6)Cycle 3000Cycle 4000Grade 3 or higher WBC count decreased, n (%) *Cycle 120 (11.2)20 (11.3)40 (11.3)Cycle 28 (4.7)2 (1.1)10 (2.9)Cycle 32 (1.2)1 (0.6)3 (0.9)Cycle 44 (2.4)2 (1.1)6 (1.8)Note: IQR, interquartile range; FN, febrile neutropenia; WBC, white blood cell.*The denominator indicates number of patients with mecapegfilgrastim for prophylaxis use in this cycle. Citation Format: Min He, Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Shulin Liu, Ping Yan, Jianjun Zou. Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-18-10.
41
Kuleshova, Nadezhda E., Alexander V. Vvedenskii, Elena V. Bobrinskaya та Elena В. Rychkova. "Роль структурно-морфологического состояния поверхности платины в кинетических и термодинамических характеристиках процесса адсорбции аниона серина". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 1 (2019): 72–83. http://dx.doi.org/10.17308/kcmf.2019.21/718.
Full textAbstract:
Исследована адсорбция аниона серина на гладком Pt и Pt(Pt)-электроде. Методом кривых заряжения получены стационарные и кинетические изотермы адсорбции. Установлено, что как на гладком, так и Pt(Pt)-электроде, кинетика исследуемых процессов подчиняется уравнению Рогинского-Зельдовича, а стационарное заполнение описывается изотермой Темкина. При этом адсорбция аниона серина на Pt(Pt) сопровождается диссоциацией адсорбата. Найдены основные термодинамические характеристики (константа адсорбционного и изменение свободной энергии Гиббса) процесса адсорбции аниона серина на обоих электродах.
 
 
 ЛИТЕРАТУРА
 
 Damaskin B., Petrii A. O., and Batrakar V.Adsorption of Organic Compounds on Electrodes. Plenum Press, New York, 1973.
 Sobkowski J., Juzkiewics-Herbish M. Metall/Solution Interface: an Experimental Approach, Modern Aspects of Electrochemistry, no. 31. Eds. by J. O¢ Bockris, R. E. White and B. E. Conway. Plenum Press, New York, London, 1997, p. 1.
 Frumkin A. N. Isbrannie trudi: Electrodnie processi, [Selected Works: Electrode Processes]. Moscow, Nauka Publ., 1987. 336 p. (in Russ.)
 Delahey P. Dvoinoi sloi i kinetika elektrodnih processov, [Double Layer and Kinetics of Electrode Processes]. Moscow, Mir Publ., 1967, 351 p. (in Russ.)
 Gileadi E. and Conway B. in:Modern Aspects of Electrochemistry, no. 3 Eds. by J. O’M. Bockris and B. Conway. Butterworths, London, 1964.
 Electrocatalysis. Ed. by J. Lipkowski, P. N. Ross. Wiley, VCH, New York, Chichester, Weinheim, Brisbake, Singarope, Toronto, 1998, 376 p.
 Bockris J. O. M., Shahed U. Khan M. Surface Electrochemistry: a Molecular Level Approach. Plenum Press, New York, London, 1993, 1014 p.
 Applied Infrared Spectroscopy. By A. Lee Smith. Wiley, Chichester, 1979.
 Gale J. Spectroelectrochemistry: Theory and Practice. Plenum Press, New York, 1988, p. 189.
 Tehnika eksperimentalnih rabot po electrohimii, korrosii I poverhnostnoi obrabotke metallov [Technique of Experimental Work on Electrochemistry, Corrosion and Surface Treatment of Metals]. Ed. by A. T. Kuna. Saint Petersburg, Khimiya Publ., vol. , 1994, 560 p. (in Russ.)
 Lasia A. Electrochemical Impedance Spectroscopy and its Application. Modern Aspects of Electrochemistry. Eds. by B. E. Conway, J. O.` Bockris and R. E. White. Kluwer Acad, Plenum Publ., New York, Boston, Dordrecht, London, Moscow, 1999, p. 143.
 Metodi ismerenii v elektrohimii [Measurement Methods in Electrochemistry]. Ed. by Eger, A. Zalkind. Moscow, Mir Publ., 1997, 585 p. (in Russ.)
 Theory of Chemisorption. by J. Smith. Berlin, Springer, 1980, 240 p.
 Horányi G. Electroanalyt. Chem., 1975, vol. 64, iss. 1, pp. 15-19. https://doi.org/10.1016/0368-1874(75)80108-0 
 Huerta F., Morallon E., Cases F., Rodes A., Vazquez J. L., Aldaz A. Electroanal. Chem., 1997, vol. 421, iss. 1-2, pp. 179-185. https://doi.org/10.1016/s0022-0728(96)04820-6 
 Huerta F., Morallon E., Cases F., Rodes A., Vazquez J. L., Aldaz A. Electroanal. Chem., 1997, vol. 421, iss. 1-2, pp. 155-164. https://doi.org/10.1016/s0022-0728(97)00542-1
 Huerta F., Morallon A., Vazquez J. L, Quijada C., Berlouis L. Electroanal. Chem., 2000, vol. 489, iss. 1-2, pp. 92-95. https://doi.org/10.1016/s0022-0728(00)00202-3
 Shi-Gang Sun,Jian-Lin Yao, Qi-Hui Wu, Zhong-Qun Tian. Langmuir, 2002, vol. 18, iss. 16, pp. 6274-6279. https://doi.org/10.1021/la025817f 
 Tumanova E. A., Safonov A. Yu. Elektrokhimiya [Russian Journal of Electrochemistry], 1998, vol. 34, iss. 2, p. 153. (in Russ.)
 Marangoni D. G., Smith R. S., Roscoe S. G., Marangoni D. G. J. Chem., 1989, vol. 67, iss. 5, pp. 921-926. https://doi.org/10.1139/v89-141
 Ogura K., Kobayashi M., Nakayama M., Miho M. Electroanal. Chem., 1998, vol. 449, iss. 1-2, pp. 101-109. https://doi.org/10.1016/s0022-0728(98)00015-1
 Gu Y. J., Chen S. P., Sun S. G., Zhou Z. Y. Langmuir, 2003, vol. 19, iss. 23, pp. 9823-9830. https://doi.org/10.1021/la034758i
 Huerta F., Morallon E., Cases F., Rodes A., Vazquez J. L., Aldaz A. Electroanal. Chem., 1997, vol. 431, iss. 2, pp. 269-275. https://doi.org/10.1016/s0022-0728(97)00212-x
 Huerta F., Morallon E., Vazquez J. L., Aldaz A. Electroanal. Chem., 1999, vol. 475, iss. 1, pp. 38-45. https://doi.org/10.1016/0022-0728(91)85503-h
 Horanyi G. Electroanal. Chem., 1991, vol. 304, iss. 1-2, pp. 211-217. https://doi.org/10.1016/s0022-0728(97)00212-x
 Kong De-Wen, Zhu Tian-Wei, Zeng Dong-Mei, Zhen Chun-Hua, Chen Sheng-Pei, Sun Shi-Gan. J. Chinese Universitie, 2009, vol. 30, no. 10, p. 2040.
 Safonova T. Y., Hidirov Sh. Sh., Petrii O. A. Elektrokhimiya [Russian Journal of Electrochemistry], 1984, vol. 20, iss. 12, p. 1666. (in Russ.)
 Kuleshova N. E., Vvedenskyi A. V., Bobrinskaya E. V. Electrokchimiya [Russian Journal of Electrochemistry], 2018, vol. 54, iss. 7, pp. 592-597. https://doi.org/10.1134/s1023193518070042
 Frumkin A. N., Podlovchenko B. I. AN SSSR, 1963, vol. 150, iss. 2, p. 349. (in Russ.)
 Podlovchenko B. I., Iofa Z. A. Journal fisicheskoi himii [Russian Journal of Physical Chemistry A], 1964, vol. 38, no. 1, p. 211. (in Russ.)
 Damaskin B. B., Petrii O. A., Tsyrlina G. A. Electrokhimiya [Electrochemistry]. Moscow, Khimiya Publ., 2001, 623 p. (in Russ.)
 Damaskin B. , Petrii O. A., Vvedenie v electrokhimiceskyu kinetiku [Introduction to Electrochemical Kinetics]. Moscow, Vyshaya Shkola Publ., 1983, 399 p. (in Russ.) 
 Frumkin A. N., Bagotskii V. S., Iofa Z. A. Kabanov B. N. Kinetika elektrodnyh processov [Kinetics of Electrode Processes]. Moscow, Izdat. Moskovs.Universiteta Publ., 1952, 319 p. (in Russ.)
 Bobrinskaya E. V., Vvedenskyi A. V., Kartashova T. V., Krashenko T. G. Korrosia: materialy i zashita [Corrosion: Materials, Protection], 2013, no. 8, pp. 1-8. (in Russ.)
 Bragin O. V., Liberman A. L. Russian Chemical Reviews, 1970, vol. 39, no. 12, p. 1017. https://doi.org/10.1070/rc1970v039n12abeh002315 
 Аnderson I. R., Macdonald R. I., Shimoyama Y. Catalysis, 1971, vol. 20, № 2, p. 147. https://doi.org/10.1016/0021-9517(71)90076-5 
 Levitskii L, Minachev Kh. M. In: Mechanisms of Hydrocarbon Reactions. 1973, Budapest, Academiai Kiado, 1975, Preprint, no. 15, p. 81.
 Anderson R., Baker B. G. Chemisorption and Reactions on Metallic Films. London, New-York. Acad. Press, 1971, p. 63.
 Bragin O. V., Preobrazenskii A. V., Liberman A. L., Kazanskii B. A. Kinetica i katalys [Kinetics and Catalysis], 1975, vol. 16, no. 2, p. 472. (in Russ.)
 Maire G., Corolleur C., Juttard D., Gault F. G. Catalysis, 1971, vol. 21, iss. 2, рp. 250-253. https://doi.org/10.1016/0021-9517(71)90143-6 
 Corolleur C., Corolleur S., Gault F. G. Catalysis, 1972, vol. 24, iss. 3, pp. 385-400. https://doi.org/10.1016/0021-9517(72)90123-6
 Paal Z., Tetenyi P. Chim. Acad. Sci. Hung., 1972, vol. 72, no. 3, p. 277.
 Barron Y., Maire G., Muller J. M., Gault F. G. Catalysis, 1966, vol. 5, iss. 3, pp. 428-445. https://doi.org/10.1016/s0021-9517(66)80062-3
 Muller J. M., Gault F. G. Catalysis, 1972, vol. 24, iss. 2, pp. 361-364. https://doi.org/10.1016/0021-9517(72)90083-8 
 Contreras A. M., Grunes J., Yan X.-M., Liddle A., Somorjai G. A. Topics in Catalysis. 2006, 39, iss. 3–4, pp. 123-129. https://doi.org/10.1007/s11244-006-0047-0 
 Khazova A. M., Vasil’ev U. B., Bagotskii V. S. Soviet Electrochemistry, 1967, vol. 3, no. 7, p. 1020. (in Russ.)
 Podlovchenko B. I., Petuhova R. P.Soviet Electrochemistry, 1972, vol. 8, no. 6, p. 899. (in Russ.)
 
 
42
"MSOM Society Student Paper Competition: Abstracts of 2021 Winners." Manufacturing & Service Operations Management 24, no. 3 (2022): 1872–74. http://dx.doi.org/10.1287/msom.2022.1097.
Full textAbstract:
The journal is pleased to publish the abstracts of the six finalists of the 2021 Manufacturing and Service Operations Management Society’s student paper competition. The 2021 prize committee was chaired by Vishal Agrawal (Georgetown University), Florin Ciocan (INSEAD), and Yanchong Zheng (Massachusetts Institute of Technology). The judges were Adam Elmachtoub, Adem Orsdemir, Amrita Kundu, Antoine Desir, Anyan Qi, Arian Aflaki, Arzum Akkas, Ashish Kabra, Bin Hu, Bora Keskin, Brent Moritz, Can Zhang, Chloe Kim Glaeser, Dan Iancu, Daniel Freund, Daniel Lin, Daniela Saban, David F. Drake, Dawson Kaaua, Divya Singhvi, Ekaterina Astashkina, Elena Belavina, Elodie Adida, Enis Kayis, Ersin Korpeoglu, Evgeny Kagan, Fabian Sting, Fanyin Zheng, Fei Gao, Fernanda Bravo, Francisco Castro, Georgina Hall, Gonzalo Romero, Guangwen Kong, Guoming Lai, Hamsa Bastani, Hessam Bavafa, Hummy Song, Ioannis (Yannis) Stamatopoulos, Ioannis Bellos, Iris Wang, Jake Feldman, Jason Acimovic, Jiankun Sun, Jiaru Bai, John Silberholz, Joline Uichanco, Jonas Oddur Jonasson, Jose Guajardo, Kaitlin Daniels, Kenan Arifoglu, Lennart Baardman, Leon Valdes, Lesley Meng, Luyi Gui, Luyi Yang, Mary Parkinson, Mazhar Arikan, Mehmet Ayvaci, Miao Bai, Michael Freeman, Ming Hu, Morvarid Rahmani, Mumin Kurtulus, Nan Yang, Nektarios Oraiopoulos, Nikhil Garg, Nil Karacaoglu, Nitin Bakshi, Nur Sunar, Olga Perdikaki, Ovunc Yilmaz, Ozan Candogan, Ozge Sahin, Panos Markou, Pascale Crama, Pengyi Shi, Pnina Feldman, Qiuping Yu, Renyu Zhang, Ruslan Momot, Ruth Beer, Ruxian Wang, Saed Alizamir, Safak Yucel, Samantha Keppler, Sanjith Gopalakrishnan, Santiago Gallino, Sarah Yini Gao, Sebastien Martin, Serdar Simsek, Seyed Emadi, Shima Nassiri, Shouqiang Wang, Siddharth Singh, Simone Marinesi, So Yeon Chun, Somya Singhvi, Song-Hee Kim, Soo-Haeng Cho, Soroush Saghafian, Sriram Dasu, Stefanus Jasin, Stephen Leider, Suresh Muthulingam, Suvrat Dhanorkar, Tian Chan, Tim Kraft, Tom TAN, Tugce Martagan, Velibor Misic, Vishal Gupta, Weiming Zhu, Xiajun Amy Pan, Xiaoshan Peng, Xiaoyang Long, Yangfang (Helen) Zhou, Yehua Wei, Yiangos Papanastasiou, Ying-Ju Chen, Yinghao Zhang, Yoni Gur, Yuqian Xu, Zhaohui (Zoey) Jiang, Zumbul Atan.
43
"Jian‐Bo Zhu." Angewandte Chemie International Edition 61, no. 18 (2022). http://dx.doi.org/10.1002/anie.202202854.
Full text
44
"Jian‐Bo Zhu." Angewandte Chemie 134, no. 18 (2022). http://dx.doi.org/10.1002/ange.202202854.
Full text
45
"MSOM Society Student Paper Competition: Abstracts of 2020 Winners." Manufacturing & Service Operations Management 23, no. 3 (2021): 731–33. http://dx.doi.org/10.1287/msom.2021.1006.
Full textAbstract:
The journal is pleased to publish the abstracts of the six finalists of the 2020 Manufacturing and Service Operations Management Society’s student paper competition. The 2020 prize committee was chaired by Vishal Agrawal (Georgetown), Feryal Erhun (University of Cambridge), and Jun Li (University of Michigan). The judges were Adem Orsdemir, Antoine Desir, Anton Ovchinnikov, Anyan Qi, Arian Aflaki, Arzum Akkas, Ashish Kabra, Bin Hu, Bob Batt, Bora Keskin, Can Zhang, Carri Chan, Chloe Kim Glaeser, Daniel Lin, Eduard Calvo, Ekaterina Astashkina, Elena Belavina, Elodie Adida, Enis Kayış, Ersin Korpeoglu, Fabian Sting, Fang Liu, Fanyin Zheng, Fei Gao, Florin Ciocan, Gah-Yi Ban, Gizem Korpeoglu, Guihua Wang, Guillaume Roels, Guoming Lai, Hessam Bavafa, Hummy Song, Ioannis (Yannis) Stamatopoulos, Ioannis Bellos, Iris Wang, Itir Karaesmen, Jiankun Sun, Jiaru Bai, Jing Wu, Joann de Zegher, Joel Wooten, John Silberholz, Jose Guajardo, Kaitlin Daniels, Karen Zheng, Ken Moon, Kenan Arifoglu, Lennart Baardman, Leon Valdes, Lesley Meng, Linwei Xin, Luyi Gui, Luyi Yang, Mary Parkinson, Mazhar Arikan, Michael Freeman, Ming Hu, Morvarid Rahmani, Mumin Kurtulus, Nan Yang, Necati Tereyagoglu, Nektarios Oraiopoulos, Nikos Trichakis, Nil Karacaoglu, Nitin Bakshi, Niyazi Taneri, Nur Sunar, Olga Perdikaki, Ovunc Yilmaz, Ozan Candogan, Ozge Sahin, Panos Markou, Pascale Crama, Pengyi Shi, Pnina Feldman, Qiuping Yu, Renyu (Philip) Zhang, Robert Bray, Ruslan Momot, Ruxian Wang, Saed Alizamir, Safak Yucel, Samantha Keppler, Santiago Gallino, Serdar Simsek, Seyed Emadi, Shiliang (John) Cui, Shouqiang Wang, Simone Marinesi, So Yeon Chun, Song-Hee Kim, Soo-Haeng Cho, Soroush Saghafian, Stefanus Jasin, Suresh Muthulingam, Suvrat Dhanorkar, Tian Chan, Tim Kraft, Tom Tan, Tugce Martagan, Velibor Misic, Weiming Zhu, Xiaoshan Peng, Xiaoyang Long, Yasemin Limon, Yehua Wei, Yiangos Papanastasiou, Ying-Ju Chen, and Zumbul Atan.
46
Rodrigues, Joanne Ribeiro, Layla Rafaele Sampaio Learte, Dallyla Jennifer Moraes de Sousa, Larissa Layanna Cardoso de Sousa, Yasmin de Oliveira Cantuário, and Gleyson Moura dos Santos. "Efeito dos probióticos no tratamento de câncer colorretal." ARCHIVES OF HEALTH INVESTIGATION 8, no. 8 (2019). http://dx.doi.org/10.21270/archi.v8i8.3212.
Full textAbstract:
Introdução: O câncer é definido como uma proliferação descontrolada de células malignas em um hospedeiro e considerado uma das principais causas de morte em todo o mundo. No Brasil, o câncer colorretal é a segunda causa de morte mais comum entre mulheres e a terceira mais prevalente em homens. Muitas estratégias têm sido estudadas para auxiliar o tratamento antineoplásico. Dentro desse contexto, a ingestão de probióticos, representa uma nova opção terapêutica relevante no âmbito da nutrição. Objetivo: Realizar uma revisão sobre o uso dos probióticos no tratamento de pacientes com câncer colorretal. Material e Método: Trata-se de uma revisão realizada em 2018, utilizando-se 10 artigos, pesquisados nas bases indexadas BVS e PubMed e na ferramenta de pesquisa Google acadêmico. A pesquisa incluiu artigos em português e inglês publicados no período de 2010 a 2017. Resultados: O uso de probióticos demonstrou trazer efeitos positivos ao tratamento de pacientes com câncer colorretal, trazendo benefícios como: a diminuição de enterobactérias e enterococos, melhora na modulação da imunidade local, melhora dos sintomas intestinais, recuperação da função intestinal, entre outros. Conclusão: Conclui-se que apesar dos resultados positivos observados, há a necessidade de futuros estudos de longa duração para elucidar melhor essa relação.Descritores: Neoplasias Colorretais; Nutrientes; Probióticos.ReferênciasKahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S. Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Appl Microbiol Biotechnol. 2017;101(5):1999-2019.Oliveira RC, Rêgo MAV. Mortality risck of colorectal câncer in Brazil from 1980 to 2013. Arq Gastroenterol 2016;53(2)76-83.Instituto Nacional de Câncer (INCA). Tipos de câncer: colorretal. Rio de Janeiro: INCA; 2018.Instituto Nacional de Câncer (INCA). Estimativa 2016: incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2016.Brasil. Ministério da Saúde. Departamento de Informática do SUS (DATASUS). Painel de Monitoramento da Mortalidade CID-10. Brasília; 2017.Corrêa RS, Pinto JRFE, Santos LV, Góis MC, Silva RP, Silva HM. Rectal cancer survival in a Brazilian Cancer Reference Unit. J Coloproctol. 2016;36:203-7.Oliveira AL, Aarestrupo FM. Avaliação nutricional e atividade inflamatória sistêmica de pacientes submetidos à suplementação com simbióticos. ABCD arq bras cir dig. 2012;25(3):147-53.Jacoby JT, Guzzon S, Rosech LFW, Mendes RH. Uso de pré, pró e simbióticos como coadjuvantes no tratamento do câncer colorretal. Clin Biomed Res. 2017;37(3):232-46.Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep. 2015;12(4):6119-27.Chaves PL, Gorini MI. Qualidade de vida do paciente com câncer colorretal em quimioterapia ambulatorial. Rev Gaucha Enferm. 2011;32(4):767-73.Barbosa, LRLS. Perfil nutricional de pacientes em pré-operatório eletivo para câncer colorretal [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais; 2011.Denipote FG, Trindade EBSM, Burini RC. Probióticos e Prebióticos na atenção primária ao câncer de cólon. Arq Gastroenterol. 2010;47(1):93-8.Machado FF, Lazzaretti RK, Poziomyck AK. Uso de prebióticos, probióticos e simbióticos nos pré e pós- operatórios do câncer colorretal: uma revisão. Rev bras cancerol. 2014;60(4):363-70.Correia MITD, Liboredo JC, Consoli MLD. The role of probiotics in gastrointestinal surgery. Nutrition. 2012;28(3):230-34.Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199-205.Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and postoperative infectious complications in colorectal câncer surgery – a double-blind study. Aliment Pharmacol Ther. 2011;33(1):50-63.Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. 7(7);8432-40.Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G et al. A four-Probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015;39(11):2776-83.Lee JY, Chu SH, Jeon JY, Lee MK, Park JH, Lee DC et al. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis. 2014;46(12):1126-32.Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16(2):167-75.Stephens JH, Hewett PJ. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome. ANZ J Surg. 2012;82(6):420-27.Xia Y, Yang Z, Chen HQ, Qin HL. Effect of bowel preparation with probiotics on intestinal barrier after surgery for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:528-31.Zhu D, Chen X, Wu J, Ju Y, Feng J, Lu G, et al. Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(8):1190-93.Derrien M, Van Hilckama Vlieg JE. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 2015;23(6):354-366.Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C. The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfateinduced colitis or reinforce the mucus barrier in mice. J Nutr. 2005;135(12):2753-61.Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356-62.Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. 2016;7(7):8432-40.
47
Chen, Yuh-Kun, Yi-Xian Lin, and Chih-Hung Huang. "First report of youcai mosaic virus in firecracker flower (Crossandra infundibuliformis) in Taiwan." Plant Disease, May 31, 2022. http://dx.doi.org/10.1094/pdis-03-22-0704-pdn.
Full textAbstract:
Firecracker flower or crossandra (Crossandra infundibuliformis), an ornamental native to southern Asia, is commonly grown as bedding plants in the garden. In January 2021, crossandra plants showing mosaic, chlorotic ringspot, and leaf deformation (Suppl. Fig. 1) were observed at a recreational farm in Zhuolan Township (Miauli County, Taiwan) (E120°82’62’’, N24°33’30’’) . Transmission electron microscope (JEM-1400, JOEL, Japan) examination by negative staining of 10 affected plants indicated the presence of particles resembling a tobamovirus in all examined affected samples. However, no tobamovirus-like particles were observed in the crude sap prepared from healthy crossandra leaf tissues. Total RNA was extracted from affected leaves and used for RT-PCR amplification using the tobamovirus group-specific primer pair Tob Uni1 (5'-ATTTAAGTGGAGGGAAAACCACT-3’) and Tob Uni2 (5'-GTYGTTGATGAGTTCGTGGA-3’) (Letschert et al., 2002). A cDNA fragment of about 650-bp was amplified and Sanger sequenced (ABI PRISM 3730 DNA Sequencer, Biotechnology Center at National Chung Hsing University, Taichung, Taiwan ), revealing 98% sequence identity to that of a Brassica isolate of youcai mosaic virus (YoMV, AY318866). The virus was isolated through mechanical inoculation onto Chenopodium quinoa to yield two pure isolates, designated FC-1 and FC-2. Mechanical inoculation of FC-1 and FC-2 back to virus-free Crossandra infundibuliformis plants (5 for each isolate) resulted in systemic mosaic, chlorotic ringspot, and leaf deformation. All mock and healthy controls were symptomless and failed to obtain any RT-PCR products with YoMV-specific primers CPF1 (5’- ATGGTTTACAACATCACGAG-3’) and CPR1 (5’-CTATGTAGCTGGCGCAGTAG-3’). Systemic symptoms of mild mosaic, ringspot, leafroll, and necrosis appeared on some of the tobaccos (Nicotiana benthamiana, N. tabacum, N. rustica), and cruciferous vegetables (Brassica rapa subsp. chinensis cv. Known-You No.2), B. rapa subsp. pekinensis cv. Autumn Sun), B. oleracea var. italica cv. Ching Hua), B. oleracea var. capitata cv. Green Peak), and Raphanus sativus cv. Snow Lady). However, inoculation of FC-1 and FC-2 on pepper (Capsicum annuum cv. Blue Star) resulted in severe necrosis on leaves and necrotic sunken spots on petioles and stems causing acute wilting and quick death. In stark contrast, FC-1 and FC-2 only induced local lesions on inoculated leaves of Chenopodium quinoa, Gomphrena globose, and Carica papaya. The infectivity of FC isolates to all plants used in host range tests were further confirmed by RT-PCR as mentioned. Oligonucleotide primers (Suppl. Table 1) specifically complementary to YoMV sequence were designed and used to amplify full-length genomic sequences of FC-1 and FC-2 isolates by RT-PCR and Sanger sequencing. Sequence analysis revealed that the genome of both FC-1 and FC-2 isolates consists of 6302 nucleotides. The viral genome has four open reading frames encoding a small replicase subunit, a RNA-dependent RNA polymerase , a movement protein, and a coat protein (CP), respectively. Both sequences, which shared 99.6% identity with each other, have been deposited in the NCBI database (Genbank Accession Numbers LC701592 and LC701593). FC-1 and FC-2 and the deduced amino acid sequences of CP shared 91.2% – 98.9% and 93.4 - 99.4% similarities, respectively, to those of published YoMV strains, confirming the identity of FC-1 and FC-2. RT-PCR analyses detected YoMV in all (100%) crossandra samples collected from the field (Suppl. Fig. 2). YoMV, formerly named Chinese rape mosaic virus (CRMV) or oilseed rape mosaic virus (ORMV) (Zhu et al., 2001), has been reported to infect cruciferous, solanaceous, and ornamental crops in Asia and Europe (Ju et al., 2019). The firecracker flower is a common and popular ornamental in Taiwan, even though its economic values are not so important. However, finding YoMV in firecracker flower may have epidemiological impacts as YoMV can infect economically important cruciferous and solanaceous crops. To our knowledge, this is the first report of YoMV infecting firecracker flowers in Taiwan.
48
Binh, Chu Thanh, Nguyen Phuong Nhue, Ho Tuyen, and Bui Thi Viet Ha. "Purification and Characterization of Chitinase from the Nematode – Fungus Paecilomyces sp. P1." VNU Journal of Science: Natural Sciences and Technology 35, no. 1 (2019). http://dx.doi.org/10.25073/2588-1140/vnunst.4851.
Full textAbstract:
The nematophagous – fungi Paecilomyces sp. is curently developed as a biocontrol agent against plant parasitic nematodes (Khan et al., 2003; Yang et al., 2007). Biological control agents can infiltrate certain nematode sites and destroy them by producing some enzymes including chitinase (Khadijeh et al., 2017). The purpose of this study was to purify, determine the chitinase activity from Paecilomyces sp. P1. With Lugol reagent, chitinase of this strain was characterized by diffusion on agar plate. Chitinase specific activity was determined by measuring the release of reducing saccharides from colloidal chitin by the N-acetyl-glucosamine-dinitrosalicylate method at 540 nm. By using the saturated (NH4)2SO4 precipitation at 65% concentration, DEAE A-50 ion exchange chromatography and SDS - PAGE concentration 12.5%, chitinase molecules weigh nearly 50kDa, having a specific activity of 133,3 U/mg, 2,1-fold higher than that of supernatant. Furthermore, method of testing with the nematode Meloidogyne sp., the ability to kill nematodes of Paecilomyces sp. P1 reached 58% efficiency in 96h. These results were a scientific basis for the application of Paecilomyces sp. P1 in the production of nematode insecticides.
 Keywords
 Paecilomyces sp. P1; chitinase; purify, biocontrol, Meloidogyne sp
 References
 
 [1] Nguyễn Ngọc Châu, Tuyến trùng thực vật và cơ sở phòng trừ, NXBKHKTHN, 2003.[2] Nguyễn Hữu Quân, Vũ Văn Hạnh, Quyền Đình Thi, Phạm Thị Huyền, Tinh sạch và đánh giá tính chất lý hóa của chitinase từ nấm Lecanicillium lecanii, Kỷ yếu Hội nghị Công nghệ Sinh học toàn quốc, 1 (2013) 426.[3] CM Baratto, V Dutra, JT Boldo, LB Leiria, MH Vainstein, A. Schrank Isolation, characterization and transcriptional analysis of the chitinase chi2 gene (DQ011663) from the biocontrol fungus Metarhizium anisopliae var. anisopliae., Curr Microbiol, 53 (2006) 217.[4] D. Wharton,. Nematode eggshells, Parasitology 81 (1980) 447.[5] F. A. Zaki, D. S. Bhatti , Effect of castor (Ricinus communus) and the biocontrol fungus Paecilomyces lilacinus on Meloidogyne javanica, Nematologica 36 (1980) 114.[6] H. M. Hussein Al Ajrami., Evaluation the Effect of Paecilomyces lilacinus as a Biocontrol Agent of Meloidogyne javanica on Tomato in Gaza Strip, Faculty of science Master of Biological Sciences Microbiology., 2016.[7] J. De la Cruz, A Hidalgo-Gallego, JM Lora, T Benitez, JA Pintor-Toro, A Llobell , Isolation and characterization of three chitinases from Trichoderma harzianum., Eur. J. Biochem,. 206 (1992) 859.[8] JLD Marco, MC Valadares-Inglis . Purification and characterization of an N-acetylglucosaminidase produced by a Trichodermaharzianum strain which controls Crinipellis perniciosa. Appl. Microbiol. Biotechnol. 64 (2003) 70.[9] JLD Marco , LHC Lima, MV Sousa MV, CR Felix A Trichoderma harzianum chitinase destroys the cell wall of the phytopathogen Crinipellis perniciosa, the causal agent of witches’ broomof cocoa, J Microbiol Biotechnol 16 (2000) 383.[10] Khan Alamgir, Williams Keith, Mark P. Molloy, and Nevalainen Henlena, Purification and characterization of a serine protease and chitinases from Paecilomyces lilacinus and detection of chitinase activity on 2D gels, Protein Expression and Purification 32 (2003) 210.[11] Khadijeh Abbsi, Doustmorad ZAFARI, Robert WICK., Evaluation of chitinase enzyme in fungal isolates obtained from golden potato cyst nematode (Globodera rostochiensis) Zemdirbyste-Agriculture, 2 (2017) 179.[12] Kopparapu Narasimha Kumar, Peng Zhou, Shuping Zhang, Qiaojuan Yan, Zhuqing Liu, Zhengqiang Jiang, Purification and characterization of a novel chitinase gene from Paecilomyces thermophila expressed in Escherichia coli. Carbonhydrate Reseach 347 (2012) 155.[13] Methanee Homthong, Anchanee Kubera, Matana Srihuttagum, Vipa Hongtrakul, Isolation and characterization of chitinase from soil fungi, Paecilomyces sp. Agriculture and Natural Resources, 1 (2016) 50.[14] RS Patil, V Ghormade, MV Desphande MV ,Chitinolytic enzymes: an exploration. Enzyme Microb. Technol. 26 (2002) 473[15] RJ Leger St , RM Cooper, AK Charnley, Characterization of chitinase and chitobiase produced by the entomopathogenic fungus Metarhizium anisopliae. J. Invertebr. Pathol. 58 (1991) 415.[16] S Leger, RJ Joshi RJ, RJ Bidochka, DW Roberts . Characterization and ultrastructural localization of Metarhizium anisopliae, M. xavoviride, and Beauveria bassiana during fungal invasion of host (Manduca sexta) cuticle. Appl Environ Microbiol 62 (1996)907.[17] SC Kang, S. Park, DG Lee ,, Purification and characterization of a novel chitinase from the entomopathogenic fungus, Metarhiziumanisopliae. J Invertebr Pathol., 73 (1999) 276.[18] P.J.M Bonants, P.F.L. Fitters, H. Thijs, E. den Belder, C. Waalwijk, J.W.D.M. Henfling. A basic serine protease from Paecilomyces lilacinus with biological activity against Meloidogyne hapla eggs, Microbiology 141(1995) 75.[19] VE Tikhonov, LV Lopez-Llorca, J Salinas, HB Jansson . Purification and characterization of chitinases from the nematophagous fungi Verticillium chlamydosporium and V. suchlasporium, Fungal Genet Biol (2002) 67[20] Van Nam Nguyen, YJ Kim, KT Oh, WJ Jung, RD Park , The antifungal activity of chitinases from Trichoderma aureoviride DY-59 and Rhizopus microsporus VS-9. Curr. Microbiol 56 (2008) 28.[21] Van Nam Nguyen, In-Jae Oh, Young-Ju Kim, Kil-Yong Kim, Young-Cheol Kim, Ro-Dong Par J Ind., Purification and characterization of chitinases from Paecilomyces variotii DG-3 parasitizing on Meloidogyne incognita eggs, (2009) 195[22] Z. Perveen and S. Shahzad S., , A comparative study of the efficacy of Paecilomyces species against root-knot nematode Meloidogyne incognita. Pakistan Journal of Nematology, 31 (2013) 125
49
Van Dem, Pham, Pham Trung Kien, Nguyen Thanh Trung, et al. "Clinical, Paraclinical Characteristics and Relative Risk Factors of Severe Degree in Children with COVID-19: Systematic Review." VNU Journal of Science: Medical and Pharmaceutical Sciences 38, no. 1 (2022). http://dx.doi.org/10.25073/2588-1132/vnumps.4371.
Full textAbstract:
Aim: systematic review of studies in the medical literature of children with COVID – 19 in order to provide evidence of clinical, paraclinical characteristics and relative risk factors of severe degree in children with COVID-19. Research subjects: A systematic review of studies on COVID-19 in children published in the international medical literature. Research methods: the information of research reports was selected from information posted on the COVID-19 update reporting portal of the Ministry of Health, PubMed, EMBASE, Cochrane Library, WHO COVID-19 Database, China National Knowledge Infrastructure (CNKI) Database, WanFang Database through system overview. Results: we collected 115 studies related to COVID-19 in children, published from January 2020 to August 2021, and by screening, we selected 21 studies related to clinical, paraclinical characteristics and relative risk factors of severe degree in children with COVID-19.
 Keywords:
 Variant Delta, COVID-19 in children, Clinical, Paraclinical Characteristics and risk factors of severe degree.
 References
 [1] Minnistry of Health, Dayly Recorded of COVID-19 (in Vietnamese), https://www.moh.gov.vn/ (accessed on: August 31st, 2021).[2] World Health Organization, Clinical Management Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance, 2020, 28 January 2020, pp. 1-10.[3] CDC (Centers for Disease Control and Prevention), COVID-19 Response Team, Coronavirus Disease 2019 in Children-United States, February 12-April 2, 2020, MMWR Morb Mortal Wkly Rep, 2020, Vol. 69, No, 14, pp. 422-426, https://doi.org/10. 15585/mmwr.mm6914e4.[4] J. F. Ludvigsson, Systematic review of COVID-19 in Children Shows Milder Cases and a Better Prognosis than Adults, Acta Paediatr, 2020 Jun, Vol. 109, No. 6, pp. 1088-1095, https://doi.org/10.1111.[5] CDC (Centers for Disease Control and Prevention), US COVID-19 Cases caused by Variants, Up-to-Date Info: https://www.cdc.gov/coronavirus/2019-nCoV (accessed on: August 31st, 2021).[6] N. Parri, M. L. D. Buonsenso, Children with Covid-19 in Pediatric Emergency Departments in Italy, N Engl J Med, 2020, Vol. 383, No. 2, pp. 187-190, https://doi.org/10.1056/NEJMc2007617, 2020. [7] Q. Lu and Y. Shi, Coronavirus Disease (COVID-19) and Neonate: what Neonatologist Need to Know, J Med Virol, 2020, Vol. 92, No. 6 , pp. 564-567, https://doi.org/10.1002/jmv.25740. [8] H. Tezer and T. B. Demirdrag, Novel Coronavirus Disease (COVID-19) in Children, Turk J Med Sci, 2020, Vol 50, pp. 592-603, https://doi.org/10.3906/sag-2004-17, 2020.[9] L. K. Zeng, X. W. Tao, W. H. Yuan et al., First Case of Neonate Infected with Novel Coronavirus Pneumonia in China. Front. Pediatr, 2020, Vol. 8, pp. 1-8, https://doi.org/10.3389/fped.2020.00287. [10] M. Wei, J. Yuan, Y. Liu et al., Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA, 2020, Vol. 323, No. 13, pp. 1313-1314, https://doi.org /10.1001/jama.2020.2131. [11] D. Wang, X. L. Ju, F. Xie et al., Clinical Analysis of 31 Cases of 2019 Novel Coronavirus Infection in Children from Six Provinces (Autonomous Region) of Northern China, Zhonghua Er Ke Za Zhi, 2020, Vol. 58, No. 4, pp. 269-274, https://doi.org/10.3760/cma.j.cn112140-20200225-00138, 2020. [12] S. Tiana, N. Hub, J. Lou et al., Characteristics of COVID-19 Infection in Beijing, J Infect, 2020, Vol. 80, No. 4, pp. 401-406, https://doi.org/10.1016/j.jinf.2020.02.018. [13] H. Zhu, L. Wang, C. Fang et al., Clinical Analysis of 10 Neonates Born to Mothers with 2019-nCoV Pneumonia. Transl Pediatr, 2020, Vol. 9, pp. 51-60, https://doi.org/10.21037/tp.2020.02.06. [14] Y. Dong, X. Mo, Y. Hu et al., Epidemiological Characteristics of 2143 Pediatric Patients with 2019 Coronavirus Disease in China, J Emerg Med, 2020, Vol . 58, No. 4, pp. 712-713, https://doi.org/1016/j.jemermed.2020.04.006. [15] I. Liguoro, C. Pilotto, M. Bonann et al., SARS-COV-2 Infection in Children and Newborns: A Systematic Review. SARS-COV-2 Infection in Children and Newborns: A Systematic Review, European Journal of Pediatrics, 2020, Vol. 18, 2020, pp. 1-18, https://doi.org/10.1007/s00431-020-03684-7. [16] J. Yasuhara, T. Kuno, H. Takagi, Clinical Characteristics of COVID‐19 in Children: A Systematic Review, Pediatric Pulmonology, 2020, Vol. 55, No. 10, pp. 2565-2575, https://doi.org/10.1002/ppul.24991. [17] T. H. D. Souza, J. A. Nadal, R. J. N. Nogueira et al., Clinical Manifestations of Children with COVID-19: A Systematic Review, Pediatr Pulmonol, 2021, Vol. 55, No. 8, pp. 1892-1899, https://doi.org/ 10.1002/ppul.24885. [18] Q. Shen, W. Guo, T. Guo et al., Novel Coronavirus Infection in Children Outside of Wuhan, China, Pediatr Pulmonol, 2020, Vol. 55, No. 6, pp. 1424-1429, https://doi.org/10.1002/ppul.24762. [19] H. Qiu, J.a Wu, L. Hong et al., Clinical and Epidemiological Features of 36 Children with Coronavirus Disease 2019 (COVID-19) in Zhejiang, China: an Observational Cohort Study, Lancet Infect Dis, 2020, Vol. 20, No. 6, pp. 689-696, https://doi.org/10.1016/S1473-3099(20)30198-5. [20] N. M. Mustafaa, L. A. Selimc, Characterisation of COVID-19 Pandemic in Paediatric Age Group: A Systematic Review and Meta-Analysis, J Clin Virol, 2020, Vol. 128, pp. 1-15, https://doi.org/10.1016/j.jcv.2020.104395. [21] W. Guan, Z. Y. Ni, Y. Hu et al., Clinical Characteristics of 2019 Novel Coronavirus Infection in China, 2020, N Engl J Med, Vol. 382, pp. 1708-1720, https://doi.org/10.1056/NEJMoa2002032.
50
Thi Thu Hoai, Nguyen, Nguyen Thuy Duong, Bui Thanh Tung, Dao Thi Vui, and Dang Kim Thu. "Comparing Acetylcholinesterase and Butyrylcholinesterase Inhibition Effect of Total Extract and Fractions with Alcaloid-Rich Extract of Huperzia Serrata (Thunb.) Trevis." VNU Journal of Science: Medical and Pharmaceutical Sciences 36, no. 1 (2020). http://dx.doi.org/10.25073/2588-1132/vnumps.4214.
Full textAbstract:
Herbal extract, rich with natural compounds, has been used for medicinal purpose such as treating neurological disorders such as cognitive defection for a long period of time, often without significant adverse effects. We compared AChE and BuChE – inhibition effect of total extracts and fractions of Huperzia serrata (Thunb.) Trevis. with alcaloid-rich extract. Our samples were subjected under supersonic extraction with ethanol 50o as solvent and fractionally extracted with n-hexane, EtOAc and n-butanol, respectively; alcaloid-rich extract was collected simutaneously. Ellman’s method was used to assay AChE and BuChE inhibition activity. Results: Alcaloid-rich extraction proved to be the superior AChE inhibiting agent, its activity nearly 6 fold of the most active Huperzia serrata extraction with IC50 value of 7.93 (5.43-10.98) µg/ml. While the fractions as well as the total extract did not provide any BuChE inhibition activity, alcaloid-rich extract showed weak ability (IC50 at 76.67 (64.78 – 91.84) µg/ml). Overall, the superior enzyme inhibition effect of alcaloid-rich extract might open a new approach in preventing and treating neurological disorders such as alzheimer’s.
 Keywords
 Huperzia serrata (Thunb.) Trevis, alcaloid, Acetylcholinesrerase inhibitors (AChE); butyrylcholinesterase (BuChE), Alzheimer.
 References
 [1] Dos Santos Picanco, Leide C et al., Alzheimer's disease: A review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment, Current medicinal chemistry 25(26) (2018) 3141 - 3159. https://doi.org/10.2174/0929867323666161213101126.[2] B.M. McGleenon, K.B. Dynan, A.P. Passmore, Acetylcholinesterase inhibitors in Alzheimer's disease, British journal of clinical pharmacology 48(4) (1999) 471-480. https://10.1046/j.1365-2125.1999.00026.x.[3] Agneta Nordberg, Clive Ballard, Roger Bullock, Taher Darreh-Shori, Monique Somogyi, A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease, The primary care companion for CNS disorders 15(2) (2013). https://10.4088/PCC.12r01412.[4] N.M. Ha, V.V. Dung et al., Report on the review of Vietnam’s wildlife trade policy, 2007.[5] D.H. Bich, et al., Medicinal plants and medicinal animals in Viet Nam. Science and Technics Publishing House 1 (2011) 896-897 (in Vietnamese).[6] Jia-Sen Liu, Yuan-Long Zhu, Chao-Mei Yu, You-Zuo Zhou, Yan-Yi Han, Feng-Wu Wu, Bao-Feng Qi, The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Canadian Journal of Chemistry 64(4) (1986) 837-839. https://doi.org/10.1139/v86-137.[7] Takuya Ohba, Yuta Yoshino et al., Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice, Bioscience biotechnology and biochemistry 79(11) (2015) 1838-1844. https://doi.org/10.1080/09168451.2015.1052773.[8] Ju-Yeon Park, Hyuck Kim et al., Ethanol Extract of Lycopodium serratum Thunb. Attenuates Lipopolysaccharide-Induced C6 Glioma Cells Migration via Matrix Metalloproteinase-9 Expression, Chinese Journal of Integrative Medicine 24(11) (2018) 860-866. https://doi.org/10.1007/s11655-017-2923-9.[9] M. Maridass, G. Raju, Investigation of phytochemical and antimicrobial activity of Huperzia species, Pharmacologyonline 3 (2009) 688-692.[10] George.L.Ellman, K.Diane Courtney, et al., A new and rapid colorimetric determination of acetylcholinesterase activity, Biochemical Pharmacology 7(2) (1961) 88-95. https://doi.org/10.1016/0006-2952(61)90145-9.[11] Paul T Francis, et al., The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 66(2) (1999) 137-147. http://dx.doi.org/10.1136/jnnp.66.2.137.[12] Prerna Upadhyaya, Vikas Seth, Mushtaq Ahmad, Therapy of Alzheimer’s disease: An update, African Journal of Pharmacy and Pharmacology 4(6) (2010) 408-421.[13] Hachiro Sugimoto, Hiroo Ogura, et al., Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor, The Japanese journal of pharmacology 89(1) (2002) 7-20.[14] N.T.K. Thu, et al., Acetylcholinesterase and butyrylcholinesterase inhibition effect of fractions extract of Huperzia serrata (Thunb.) Trevis. The journal of Pharmeceutical 56(11) 49-53 (in Vietnamese).[15] Xiaoqiang Ma, Changheng Tan, et al, Is there a better source of huperzine A than Huperzia serrata? Huperzine A content of Huperziaceae species in China. J Agric Food Chem, 53(5) (2005)1393-8. https://doi.org/10.1021/jf048193n.[16] Ya-Bing Yang, Xue-Qiong Yang, et al., A New Flavone Glycoside from Huperzia serrata. Chinese Journal of Natural Medicines 6(6) (2008) 408-410.[17] G.T. Ha, R.K. Wong, Y. Zhang, Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies, Chemistry & biodiversity 8(7) (2011) 1189-1204. https://doi.org/10.1002/cbdv.201000269.[18] H.Y. Zhang, X.C. Tang, Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease, Trends in pharmacological sciences 27(12) (2006) 619-625. https://doi.org/10.1016/j.tips.2006.10.004.[19] Y. Wang, X.C. Tang, H.Y. Zhang, Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice, Journal of neuroscience research 90(2) (2012) 508-517. https://doi.org/10.1002/jnr.22775.[20] C.Y. Wang, et al., Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model, Neuropsychopharmacology 36(5) (2011) 1073-1089. https://doi.org/10.1038/npp.2010.245.[21] R.K. Gordon, et al., The NMDA receptor ion channel: a site for binding of Huperzine A, Journal of applied toxicology 21(S1) (2001) S47-S51. https://doi.org/10.1002/jat.805.[22] M. Rafii, et al., A phase II trial of huperzine A in mild to moderate Alzheimer disease, Neurology 76(16) (2011) 1389-1394. https://doi.org/10.1212/WNL.0b013e318216eb7b.[23] N.H. Greig, et al., A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase, Current medical research and opinion 17(3) (2001)1 59-165.[24] A. Ferreira, et al., Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology, Phytochemistry reviews 15(1) (2016) 51-85. https://doi.org/10.1007/s11101-014-9384-y.